Document:

Award Contract

 Exhibit 4.16 

 

 

  
 * Confidential
Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) RATING DO C9 PAGE OF PAGES 1 25
2. CONTRACT (Proa. Inst. Indent.) NO. W9113M-10-C-0057 3. EFFECTIVE DATE 14 July 2010 4. REQUISITION/PURCHASE REQUEST/PROJECT NO. SEE SCHEDULE 5. ISSUED BY USASMDC/ARSTRAT SMDC-RDC-EB 64 THOMAS JOHNSON DRIVE FREDERICK MD 21702 CODE W9113M 6.
ADMINISTERED BY (if other than item 5) DCM SEATTLE CORPORATE CAMPUS EAST III 3009 112 TH AVE., NE, SUITE 200 BELLEVUE WA 98004-8019 CODE S4801A 7. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) TEKMIRA PHARMACEUTICALS
CORPORTION 8900 GLENLYON PKY SUITE 100 BURNABY V5J5J8 8. DELIVERY  ̈ FOB ORIGIN  ̈ OTHER (See below) 9. DISCOUNT FOR PROMPT PAYMENT 10. SUBMIT INVOICES (4
copies unless otherwise specified) TO THE ADDRESS SHOWN IN ITEM G CODE L8144 FACILITY CODE 11. SHIP TO/MARK FOR See Schedule CODE 12. PAYMENT WILL BE MADE BY DFAS-COLUMBUS CETER DFAS-CO/WEST ENTITLEMENT OPERATION PO BOX 182381 COLUMBUS OH 43218-2381
CODE HQ0339 13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION: 10 U.S.C. 2304(c) ( ) 41 U.S.C 263(e) ( ) 14. ACCOUNTING AND APPROPRIATION DATA SEE SCHEDULE 15A. ITEM NO. 15B. SUPPLIES/SERVICES SEE SCHEDULE 15C.QUANTITY 15D. UNIT 15E. UNIT
PRICE 15F. AMOUNT 15G. TOTAL AMOUNT OF CONTRACT $34,747,879 16. TABLE OF CONTENTS (X) SEC. DESCRIPTION PAGE(S) PART 1-THE SCHEDULE A. SOLICITATION/CONTRACT FORM 1-2 B. SUPPLIES OR SERVICES AND PRICES/COSTS 3-6 C. DESCRIPTION/SPECS/WORK STATEMENT 7
D. PACKAGING AND MARKING 8 E. INSPECTION AND ACCEPTANCE 9 F. DELIVERIES OR PERFORMANCE 10 G. CONTRACT ADMINISTRATION DATA 11-13 H. SPECIAL CONTRACT REQUIREMENTS 14-17 (X) SEC. DESCRIPTION PAGE(S) PART II – CONTRACT CLAUSES I CONTRACT CLAUSES
18-24 PART III-LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH. J. LIST OF ATTACHMENTS 25 PART IV – REPRESENTATIONS AND INSTRUCTIONS K. REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS L. INSTRS., CONDS., AND NOTICES TO OFFERORS M.
EVALUATION FACTORS FOR AWARD CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE 17. CONTRACTOR’S NEGOTIATED AGREEMENT (Contractor is required to sign this document and return 1 copies to issuing office.) Contractor agrees to furnish
and deliver all items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed
by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are listed herein.)
18. AWARD (Contractor is not required to sign this document.) Your offer on Solicitation Number W9113M-09-R-0008 , including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the
terms listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government’s solicitation and your offer, and (b) this award/contract. No further contractual document is
necessary. 19A. NAME AND TITLE OF SIGNER (Type or Print) [*] 20A. NAME OF CONTRACTING OFFICER [*] 19B. NAME OF CONTRACTOR BY: [*] (Signature of person authorized to sign) 19C. DATE SIGNED JULY 13, 2010 20B. UNITED STATES OF AMERICA BY: [*]
(Signature of person authorized to sign) 20C. DATE SIGNED JULY 14, 2010 AUTHORIZED FOR LOCAL REPRODUCTION Previous edition is usable STANDARD FORM 26 (REV. 4/2006 Prescribed by GS – FAR (48CER) 53.214(a) * Confidential Treatment Requested.

 W9113M-10-C-0057 
  Page 
 2
 of 24 
  

 Section A – Solicitation/Contract Form 
 SECTION A 
 CONTINUATION OF FORM 26 
 Award is hereby made for the Advanced Development through licensure of a Hemorrhagic Fever Virus Therapeutic. 
 The Tekmira Pharmaceuticals Corporation proposal dated 1/29/2010 and as revised on 3/22/2010 and 4/30/2010, is incorporated into contract No. W9113M-10-C-0057 in its entirety with the following revisions:

  

	 	1.	A post award audit will be requested by the Government to determine the adequacy of Tekmira Pharmaceuticals Corporation’s accounting system. Vouchers submitted
prior to an accounting system adequacy determination by the DCAA, and approval by the ACO, are subject to latter adjustment. Each voucher submitted shall have [*]% decremented to ensure the Governments rights are adequately protected until such time
as the accounting system is approved. Upon approval, Tekmira may voucher for the withheld amounts for payment. 

  

	 	2.	Section G has been revised to include local WAWF clause to include the type and codes required for payment purposes. 

3. Section H has been revised to include paragraphs H. 6, requirements from the RFP at Section M.3.4 Post-Award Evaluations of
Contractors’ Performance and Down-Select Criteria. 
 4. The following clauses are hereby added to Section I by reference:

 52.215-16 Facilities Capital Cost of Money (June 2003) 

252.204-7008 Export Controlled Items (April 2010) 
 5. The following clause is hereby deleted from Section I as follows: 
 52.232-25
Prompt Payment (OCT 2008) 
 6. The following clause is hereby revised to remove the last sentence: 

52.217-7 Option for Increased quantity-Separately Priced Line Item (MAR 1989) 
 7. Section 2.2 (and any associate entries in the IMS and/or CWBS) of the Tekmira SOW, Section J, Attachment 1 is hereby removed, as this effort is being conducted prior to date of award and is not
covered by this contract. 
 8. Only those exceptions noted in the Tekmira Final Proposal Revision dated 4/30/2010, pages 3-5
are incorporated into this contract. 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 3
 of 24 
  

 Section B - Supplies or Services and Prices 

 

																			
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	 	  	UNIT	 	  	UNIT PRICE	 	  	AMOUNT	 
	 0001
	  		  				  	 	Lot	  	  				  	$	[*	] 
			
		  	 Advanced Development of Hemorrhagic
	   
	  			
		  	 CPIF
	   
	  			
			
		  	Fever Virus Therapeutic. Delivery of the developmental therapeutic end item that has successfully achieved all activities associated with completing FDA Phase 1
Clinical Trials exclusive of those required to achieve Technology Readiness Level 4, to include Pre-IND, IND, and Phase I Human Safety Clincal Studies, including Management, Regulatory Affairs, all FDA submissions and official program reporting
requirements (to include EVMS if required) in accordance with the Contractor’s Statement of Work (SOW), dated 3/22/10, Attachment 1 of Section J. (Note: maturity level of candidate receiving award will determine the specific activities
awarded.) Reporting requirements are delineated in Contract Data Requirements List DD Form 1423, attached as Exhibits A001 through A006 in Section J.	         	  			
		  	 FOB: Destination
	   
	  			
		  	 TARGET COST
	   
	  	$	[*	] 
		  	 TARGET FEE
	   
	  	$	[*	] 
		  		  				  				  				  	 	 	 
		  	 TOTAL TGT COST + FEE
	   
	  	$	[*	] 
			
		  	 MINIMUM FEE
	   
	  	$	[*	] 
		  	 MAXIMUM FEE
	   
	  	$	[*	] 
		  	 SHARE RATIO ABOVE TARGET
	   
	  	 	[*	] 
		  	 SHARE RATIO BELOW TARGET
	   
	  	 	[*	] 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 4
 of 24 
  

																			
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	 	  	UNIT	 	  	UNIT PRICE	 	  	AMOUNT	 
	 000101
	  		  				  				  				  	$	[*	] 
						
		  	 Funding for CLIN 0001
	  				  				  				  			
		  	 CPIF
	  				  				  				  			
						
		  	 FOB: Destination
	  				  				  				  			
		  	 TARGET COST
	   
	  	$	[*	] 
		  	 TARGET FEE
	   
	  	$	[*	] 
		  		  				  				  				  	 	 	 
		  	 TOTAL TGT COST + FEE
	   
	  	$	[*	] 
			
		  	 MINIMUM FEE
	   
	  	$	[*	] 
		  	 MAXIMUM FEE
	   
	  	$	[*	] 
		  	 SHARE RATIO ABOVE TARGET
	   
	  			
		  	 SHARE RATIO BELOW TARGET
	   
	  			
		  	 ACRN AA
	   
	  	$	[*	] 
		  	 CIN: 000000000000000000000000000000
	   
	  			
						
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	 	  	UNIT	 	  	UNIT PRICE	 	  	AMOUNT	 
	 0002
	  		  				  	 	Lot	  	  				  	$	[*	] 
			
	 OPTION
	  	Advanced Development of Hemorrhagic	  	  			
		  	 CPIF
	  				  				  				  			
			
		  	Fever Virus Therapeutic. Delivery of the developmental therapeutic end item that has successfully achieved Phase II Pivotal Animal Efficacy Studies. This line item
includes all associated Management, Regulatory Affairs, FDA submissions and Official program reporting requirements (to include EVMS if required). In accordance with the Contractor’s Statement of Work (SOW), dated 3/22/10, Attachment 1 of
Section J. Reporting requirements are delineated in Contract Data Requirements List DD Form 1423, attached as Exhibits A001 through A006 in Section J.	       	  			
		  	 FOB: Destination
	  				  				  				  			
		  	 TARGET COST
	   
	  	$	[*	] 
		  	 TARGET FEE
	   
	  	$	[*	] 
		  		  				  				  				  	 	 	 
		  	 TOTAL TGT COST + FEE
	   
	  	$	[*	] 
			
		  	 MINIMUM FEE
	   
	  	$	[*	] 
		  	 MAXIMUM FEE
	   
	  	$	[*	] 
		  	 SHARE RATIO ABOVE TARGET
	   
	  	 	[*	] 
		  	 SHARE RATIO BELOW TARGET
	   
	  	 	[*	] 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 5
 of 24 
  

																			
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	 	  	UNIT	 	  	UNIT PRICE	 	  	AMOUNT	 
	 0003
	  		  				  	 	Lot	  	  				  	 	$        [*]	  
			
	 OPTION
	  	 Advanced Development of Hemorrhagic
	   
	  			
		  	 CPIF
	   
	  			
			
		  	Fever Virus Therapeutic. Delivery of the developmental therapeutic end item that has successfully achieved Phase III Expanded Human Safety Clinical Studies. This line
item includes all associated Management, Regulatory Affairs, FDA submissions and Official program reporting requirements (to include EVMS if required). in accordance with the Contractor’s Statement of Work (SOW), dated 3/22/10, Attachment 1 of
Section J. Reporting requirements are delineated in Contract Data Requirements List DD Form 1423, attached as Exhibits A001 through A006 in Section J.	       	  			
		  	 FOB: Destination
	   
	  			
		  	 TARGET COST
	   
	  	$	[*	] 
		  	 TARGET FEE
	   
	  	$	[*	] 
		  		  				  				  				  	 	 	 
		  	 TOTAL TGT COST + FEE
	   
	  	$	[*	] 
			
		  	 MINIMUM FEE
	   
	  	$	[*	] 
		  	 MAXIMUM FEE
	   
	  	$	[*	] 
		  	 SHARE RATIO ABOVE TARGET
	   
	  	 	[*	] 
		  	 SHARE RATIO BELOW TARGET
	   
	  	 	[*	] 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 6
 of 24 
  

																			
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	 	  	UNIT	 	  	UNIT PRICE	 	  	AMOUNT	 
	 0004
	  		  				  	 	Lot	  	  				  	$	[*	] 
			
	 OPTION
	  	Advanced Development of Hemorrhagic	  	  			
		  	 CPIF
	  				  				  				  			
			
		  	Fever Virus Therapeutic. New Drug Application and delivery of FDA licensed developmental therapeutic end item to include all New Drug Application and Licensure
activities resulting in the delivery of at least one dose of an FDA approved therapeutic. This line item includes all associated Management, Regulatory Affairs, FDA submissions and Official program reporting requirements (to include EVMS if
required), in accordance with the Contractor’s Statement of Work (SOW), dated 3/22/10, Attachment 1 of Section J. Reporting requirements are delineated in Contract Data Requirements List DD Form 1423, attached as Exhibits A001 through A006 in
Section J.	        	  			
		  	 FOB: Destination
	  				  				  				  			
		  	 TARGET COST
	   
	  	$	[*	] 
		  	 TARGET FEE
	   
	  	$	[*	] 
		  		  				  				  				  	 	 	 
		  	 TOTAL TGT COST + FEE
	   
	  	$	[*	] 
			
		  	 MINIMUM FEE
	   
	  	$	[*	] 
		  	 MAXIMUM FEE
	   
	  	$	[*	] 
		  	 SHARE RATIO ABOVE TARGET
	   
	  	 	[*	] 
		  	 SHARE RATIO BELOW TARGET
	   
	  	 	[*	] 

  

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 7
 of 24 
  

 Section C - Descriptions and Specifications 
 SECTION C 
 Contractor’s Statement of Work, dated 3/22/10, Attachment 1, Section J.

 W9113M-10-C-0057 
  Page 
 8
 of 24 
  

 Section D - Packaging and Marking 
 SECTION D 
 Packaging and Marking shall be in accordance with FDA regulations as described
in Contractor’s Statement of Work, dated 3/22/10, Attachment 1 in Section J. 

 W9113M-10-C-0057 
  Page 
 9
 of 24 
  

 Section E - Inspection and Acceptance 
 INSPECTION AND ACCEPTANCE TERMS 
 Supplies/services will be inspected/accepted at: 

 

									
	CLIN	  	INSPECT AT	  	INSPECT BY	  	ACCEPT AT	  	ACCEPT BY
	0001	  	Destination	  	Government	  	Destination	  	Government
	000101	  	N/A	  	N/A	  	N/A	  	Government
	0002	  	Destination	  	Government	  	Destination	  	Government
	0003	  	N/A	  	N/A	  	N/A	  	Government
	0004	  	Destination	  	Government	  	Destination	  	Government

 CLAUSES INCORPORATED BY REFERENCE 

 

					
	52.246-8	  	Inspection Of Research And Development Cost Reimbursement	  	MAY 2001
	52.246-16	  	Responsibility For Supplies	  	APR 1984

 CLAUSES INCORPORATED BY FULL TEXT 

 

			
	52.246-11	  	HIGHER-LEVEL CONTRACT QUALITY (FEB 1999)

 The Contractor
shall comply with the higher-level quality standard selected below. (If more than one standard is listed, the offeror shall indicate its selection by checking the appropriate block.) 

 

													
	Title	  	Number	  	Date	  	Tailoring	  	 	  	 
	X    	  	ISO 9001/2000 or higher;	  		  	
		  	Quality System in compliance with FDA Quality requirements	  		  	

 (End of clause) 

 W9113M-10-C-0057 
  Page 
 10
 of 24 
  

 Section F - Deliveries or Performance 
 DELIVERY INFORMATION 
  

									
	CLIN	  	DELIVERY DATE	  	QUANTITY	  	SHIP TO ADDRESS	  	UIC
	 0001
	  	04-NOV-2012	  	Lot	  	 Transformational Medical Technologies
 Initiative Defense Threat Reduction Agency
 8725 John J. Kingman Road, stop 6201

Fort Belvoir, VA, 22060-6201
 FOB:
Destination
	  	HDTRA1
					
	 000101
	  	N/A	  	N/A	  	N/A	  	N/A
					
	 0002
	  	11-AUG-2014	  	Lot	  	 Same as Above
 FOB:
Destination
	  	HDTRA1
					
	 0003
	  	24-AUG-2015	  	Lot	  	 Same as Above
 FOB:
Destination
	  	HDTRA1
					
	 0004
	  	03-OCT-2016	  	Lot	  	 Same as Above
 FOB:
Destination
	  	HDTRA1

 CLAUSES INCORPORATED BY REFERENCE 

 

					
	 52.242-15 Alt I
	  	Stop-Work Order (Aug 1989) - Alternate I	  	APR 1984
	 52.247-34
	  	F.O.B. Destination	  	NOV 1991

 W9113M-10-C-0057 
  Page 
 11
 of 24 
  

 Section G - Contract Administration Data 
 SECTION G 
 SECTION G 
 PAYMENTS: 
 Detailed Copies of all payment requests will be provided electronically to the
Government points of contact listed below at the same time of submission to WAWF: 
 Contracting Office: 

USASMDC 
 Attn: [*] 

64 Thomas Johnson Drive 
 Frederick, MD 21702

 Telephone: 301-619-2895 
 Fax:
301-619-5069 
 Email: [*] 

Contracting Officers Representative (COR): 

[*] 
 8725 John J. Kingman Road, stop 6201

 Fort Belvoir, VA 22060-6201 

Telephone: (703)767-2908 
 Email: [*]

 ACCOUNTING AND APPROPRIATION DATA 

AA: 970040026TM5YTMW61D255999BD33799000S49012 DODAAC: HD1115 
 AMOUNT: $[*] 
 CIN 000000000000000000000000000000: $[*] 

CLAUSES INCORPORATED BY REFERENCE 
  

					
	 252.201-7000
	  	Contracting Officer’s Representative	  	DEC 1991

 CLAUSES INCORPORATED BY FULL TEXT 

INVOICING INSTRUCTIONS 
 a. The contractor shall submit payment request electronically in accordance with DFARS 252.232-7003 utilizing Wide Area Work Flow (WAWF). The WAWF application allows DOD vendors to submit and track
invoices and receipt/acceptance documents electronically. The contractor shall register with WAWF at 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 12
 of 24 
  

 
https://wawf.eb.mil and ensure an electronic business point of contract (POC) is designated in the Central Contractor Registration site at http://www.ccr.gov within ten
(10) days after award of this contract. Payments made under this contract shall be via Electronic Funds Transfer (EFT) and shall be based on the EFT information contained in the Central Contractor Registration (CCR) database. The contractor
shall ensure that its EFT information in the CCR database remains current and correct. 
 b. Multiple pricing structures may be
utilized for this contract or, if a task ordering contract, for individual task orders issued thereunder. In order to ensure the successful flow of WAWF documents, the type of payment request submitted shall be based on the following as applicable:

                 Invoice and Receiving Report
(COMBO): applicable to Firm-Fixed-Price (FFP) contracts/task orders that include the delivery of supplies/hardware. 

                Invoice as 2-in-1: applicable to Labor Hour
and FFP contracts/task orders for services only. 

X             Cost Voucher: applicable to Time and Material
(T&M) and Cost-Reimbursement type contracts/task orders. 

                Construction Invoice: applicable to
contracts/task orders for construction. 
 c. WAWF requires the following data for each payment request: (To be provided by
the Government. If a task ordering contract, each awarded task order shall identify this information) 
 Contract/Task Order Data

  

			
	 Contractor CAGE Code:
	  	L8144
	 Issue by DODAAC:
	  	W9113M
	 Admin by DODAAC:
	  	S4801A
	 Inspect by DODAAC:
	  	S4801A
	 Accept by DODAAC:
	  	S4801A
	 Ship to DODAAC:
	  	HD1115
	 Payment by DODAAC:
	  	HQ0339

 Email Points of Contact Listing 

Inspector: TBD 
 Acceptor: TBD 

Contracting Specialist: [*] 
 Contracting
Officer: 
 Contracting Officer’s Technical Representative: [*] 
 d. Questions concerning payments shall be directed to the Defense Finance and Accounting Service (DFAS). The appropriate DFAS office is indentified in the “PAYMENT WILL BE MADE BY” block on the
contract award coversheet. Please have your contract and, if applicable, task order number ready when calling about payments. Payment and receipt information may be accessed using the DFAS web site MyInvoice. MyInvoice is a web-based application
developed specifically for contractors/vendors and Government/ Military employees to obtain invoice status. It is an interactive web-based system, accessible 24/7. Users must allow pop-up messages within this system. Your contract and, if
applicable, task order number or invoice number will be required to inquire about the status of your payment. For additional information, see the MyInvoice website at https://myinvoice.csd.disa.mil/ or visit
http://www.dfas.mil/contractorpay/ electroniccommerce/myinvoice.html. 
 e. The contractor may submit requests for
payment through WAWF not more frequently than monthly (or bi-weekly if a small business). 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 13
 of 24 
  

 f. For Labor Hour and T&M contracts/task orders, payment requests for labor shall be
based on the total labor hours/DPPH expended thereunder for the applicable billing period. These labor charges shall be derived by applying the total hours expended for each labor category multiplied by the applicable fixed-labor rates specified in
the contract/task order. Labor charges for cost-reimbursement contracts/task orders shall be based on the total hours expended for each labor category multiplied by actual direct labor rates plus applicable indirect burdens and fee. Travel and
ODC/material under T&M and Cost-Reimbursement type contracts/task orders shall be billed at actual costs. For each payment request, the contractor shall attach/upload into WAWF sufficient documentation as to how the billed amounts were
derived/calculated. 
 g. For Firm-Fixed-Price contracts/task orders, payments on the total contract price (excluding any
unexercised options) may be requested in equal monthly (or bi-weekly if a small business) amounts calculated over the life of the contract/task order unless alternative payment schedules (e.g., performance-based payments) are specified elsewhere in
the contract, or if applicable, in individual task orders. 
 h. For each payment request, the contractor shall maintain
sufficient documentation to substantiate the submitted charges. Such documentation shall include evidence of actual expenditures/payment such as individual daily job timecards, subcontractor/vendor invoices and payment receipts, or other
substantiation specified by the Contracting Officer. Such data shall be maintained and readily available for audit purposes, but shall not be included with the WAWF submission. The contractor shall provide such documentation within 7 days of request
by the Procuring Contracting Officer, Administrative Contracting Officer, or DCAA auditor. 
 i. The contractor shall ensure
that each payment request submitted in WAWF denotes that the Contracting Officer and Contract Specialist will receive a copy of the payment request notice. 
 j. Except for FFP contracts/task orders, the contractor and each assignee under an assignment entered into under this contract or, if applicable, an individual task order and in effect at the time of
final payment on this contract or, if applicable, an individual task order issued under this contract, shall execute and deliver, at the time of and as a condition precedent to, any final payment thereunder, a release discharging the Government, its
officers, agents, and employees, of and from all liabilities, obligations, and claims arising out of, or under, the specific contract/task order. These closing documents shall be submitted with the final payment request. 

k. The contractor shall submit final payment requests for Labor Hour and FFP contracts/task orders within 120 days (or longer if approved
in writing by the Contracting Officer) after contract/order completion. For T&M or Cost-Reimbursement type contracts/task orders, the contractor shall prepare a final payment request within 120 days (or longer if approved in writing by the
Contracting Officer) after settlement of the final annual indirect cost rates to reflect the settled amounts and rates for the performance period covered. The cognizant DCAA shall perform a final audit on the contractor’s final payment request
to determine allowable costs. The Administrative Contracting Officer may utilize the cumulative allowable worksheets included with the DCAA incurred cost audit reports in lieu of requesting DCAA to perform the final closeout audit to determine the
final costs on the cost reimbursable portions of the contract/task order. 

 W9113M-10-C-0057 
  Page 
 14
 of 24 
  

 Section H - Special Contract Requirements 
 CLAUSES INCORPORATED BY REFERENCE 
  

					
	 252.234-7002
	  	Earned Value Management System	  	APR 2008

 SECTION H 

H. 1 SECURITY CONSIDERATIONS 
 At this time,
there are no anticipated classified materials or performance required for this acquisition. However, if mandated by a program and/or contractual requirements in the future, the selected contractor(s) may need to have a Facility Security Clearance
and Personnel Security Clearances to maintain a safeguarding capability through SECRET clearance level in accordance with the Industrial Security Regulation, DoD 5220.22-R and the National Industrial Security Program Operating Manual, DoD 5220.22-M.
Following contract award, should classified information be required, it will be safeguarded in accordance with these documents, including submission of a DD Form 254 and Government generation of a Security Classification Guide. The contractor(s)
will receive routine Government audits of their industrial security management system to ensure adequate security safeguards have been established and maintained. The Government’s assigned Industrial Security Representative will determine the
frequency of such formal reviews, but a review will normally be conducted on an annual basis. 
 Although not anticipated at this time, should
performance of the contract(s) require physical access to a Federally-controlled facility, the contractor(s) shall comply with the Office of Management and Budget Guidance M-05-24, dated August 5, 2005, Implementation of Homeland Security
Presidential Directive 12-Policy for a Common Identification Standard for Federal Employees and Contractors. The Government will coordinate all actions necessary for access to a Federally-controlled facility to ensure proper and only essential
access is provided to the contractor(s). 
 Ebola and Marburg viruses are category A select agents as classified by the CDC and require BSL-4
containment facilities. Therefore, this contract will involve access to Biological Select Agents and Toxins (BSAT). The Contractors will be required to certify they are registered in accordance with Federal, State, and local regulations, including
with the CDC and the Animal and Plant Health Inspection Service. The Contractor will be required to comply with DoD Directive 5210.88, Safeguarding Biological Select Agents and Toxins; DoDI 5210.89, Minimum Security Standards for Safeguarding
Biological Select Agents and Toxins; Army Regulation (AR) 50-1, Biological Surety; and AR 190-17, Biological Select Agents and Toxins Security Program; and AR 190-51, Army Physical Security Program. 

 W9113M-10-C-0057 
  Page 
 15
 of 24 
  

 The HFV Class will not generate or require the use of classified information or classified material of
any kind. The data generated in the projects would be considered “unclassified controlled information” at best. The Contractor must meet the requirements for working with unclassified controlled information set forth by DoDD 5200.1.

 The Contractor will comply with DoDD 5200.1 Appendix C in the marking of all documents and media items, safeguarding of all information,
accessing of all information, storage of all project data, reproduction and disposal of all information, handling and transport of all information, management of the Information Security Program, and limited control and distribution of some project
documents. 
 H.2 TEST AND EVALUATION 

The HFV Class of Therapeutics will be developed in full accordance with FDA regulations and guidelines established by CFR 21, the Pure Food and Drug Act.
The FDA mandates test and evaluation processes that follow a series of phases that establish the effectiveness and safety of new drugs. The FDA issues extensive mandatory guidance and requires submission of substantive evidence for FDA review. Only
after FDA approval can work proceed from one phase to the next. The FDA process is mandatory for licensure. The Government will utilize the Contractor’s validated information and FDA process documentation in evaluating progress and conformance
with TPP Guidelines. 
 H.3. PROHIBITION OF USE OF LABORATORY ANIMALS 
 Information and guidance is provided at the following web site: 

https://mrmc.amedd.army.mil/index.cfm?pageid=research_protections.acuro 
 https://mrmc.amedd.army.mil/rodorpaurd.asp 
 ** PROHIBITION – READ FURTHER FOR
DETAILS ** 
 Notwithstanding any other provisions contained in this award or incorporated by reference herein, the recipient is expressly
forbidden to use or subcontract for the use of laboratory animals in any manner whatsoever without the express written approval of the US Army Medical Research and Materiel 

 W9113M-10-C-0057 
  Page 
 16
 of 24 
  

 
Command, Animal Care and Use Office. You will receive written approval to begin research under the applicable protocol proposed for this award from the US Army Medical Research and Materiel
Command, Animal Care and Use Office under separate letter to the recipient and Principal Investigator. A copy of this approval will be provided to the US Army Space and Missile Defense Command for the official file. Non-compliance with any provision
of this clause may result in the termination of the award. 
 H.4. PROHIBITION OF USE OF HUMAN SUBJECTS 

Information and guidance is provided at the following web site: 
 https://mrmc.amedd.army.mil/rodorphrpo.asp 
 ** PROHIBITION – READ FURTHER FOR
DETAILS ** 
 Research under this award involving the use of human subjects may not begin until the U.S. Army Medical Research and Materiel
Command’s Office of Research Protections, Human Research Protections Office (HRPO) approves the protocol. Written approval to begin research or subcontract for the use of human subjects under the applicable protocol proposed for this award will
be issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to the US Army Space and Missile Defense Command for the
official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award. 
 H.5.
PROHIBITION OF USE OF HUMAN ANATOMICAL SUBSTANCES 
 Information and guidance is provided at the following web site: 

https://mrmc.amedd.army.mil/rodorphrpo.asp 

 W9113M-10-C-0057 
  Page 
 17
 of 24 
  

 ** PROHIBITION – READ FURTHER FOR DETAILS ** 

Research at funded institutions using human anatomical substances may not begin until the U.S. Army Medical Research and Materiel Command’s Office
of Research Protections, Human Research Protections Office (HRPO) approves the protocol. Written approval to begin research or subcontract for the use of human anatomical substances under the applicable protocol proposed for this award will be
issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to the US Army Space and Missile Defense Command for the
official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award. 
 H.6.
Post-Award Evaluations of Contractors’ Performance and Down-Select Criteria 
 H.6.1 This acquisition provides that Contractors with
products that fail in development or in default of contract requirements will not be continued by option exercise (if not defaulted sooner). 

H.6.2 All other performing Contractors will not be denied the opportunity to continue performance under an option clause by the Government’s
decision to exercise or not exercise an option, or otherwise, absent a best value comparative evaluation using established RFP evaluation criteria. The criteria shall include, but not be limited to, post-award performance, the Government’s
preference to avoid therapeutics addressing duplicative indications and the Anti-Viral TPP Guidelines. Trade-offs can be considered at down-select points in the evaluation of each candidate against the evaluation criteria. The Government’s
right to unilaterally decide not to exercise all options and to discontinue the development of all HFV therapeutics is paramount. 
 H.6.3 In
the event a best value comparative evaluation becomes necessary or is desired at a down- select point, selection shall be based on evaluation of the contractors’ actual post-award contract performance against evaluation criteria established in
the RFP to include the Anti-Viral TPP Guidelines and the Government’s preference to avoid therapeutics addressing duplicative indications. 

 W9113M-10-C-0057 
  Page 
 18
 of 24 
  

 Section I - Contract Clauses 
 CLAUSES INCORPORATED BY REFERENCE 
  

					
	52.202-1	  	 Definitions
	  	JUL 2004
	52.203-3	  	 Gratuities
	  	APR 1984
	52.203-5	  	 Covenant Against Contingent Fees
	  	APR 1984
	52.203-6	  	 Restrictions On Subcontractor Sales To The Government
	  	SEP 2006
	52.203-7	  	 Anti-Kickback Procedures
	  	JUL 1995
	52.203-8	  	 Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity
	  	JAN 1997
	52.203-10	  	 Price Or Fee Adjustment For Illegal Or Improper Activity
	  	JAN 1997
	52.203-12	  	 Limitation On Payments To Influence Certain Federal Transactions
	  	SEP 2007
	52.203-14	  	 Display of Hotline Poster(s)
	  	DEC 2007
	52.204-4	  	 Printed or Copied Double-Sided on Recycled Paper
	  	AUG 2000
	52.204-7	  	 Central Contractor Registration
	  	APR 2008
	52.204-10	  	 Reporting Subcontract Awards
	  	SEP 2007
	52.209-6	  	 Protecting the Government’s Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for
Debarment
	  	SEP 2006
	52.211-5	  	 Material Requirements
	  	AUG 2000
	52.215-2	  	 Audit and Records—Negotiation
	  	MAR 2009
	52.215-2 Alt I	  	 Audit and Records—Negotiation (Mar 2009) Alternate I
	  	MAR 2009
	52.215-8	  	 Order of Precedence—Uniform Contract Format
	  	OCT 1997
	52.215-10	  	 Price Reduction for Defective Cost or Pricing Data
	  	OCT 1997
	52.215-11	  	 Price Reduction for Defective Cost or Pricing Data—Modifications
	  	OCT 1997
	52.215-12	  	 Subcontractor Cost or Pricing Data
	  	OCT 1997
	52.215-13	  	 Subcontractor Cost or Pricing Data—Modifications
	  	OCT 1997
	52.215-15	  	 Pension Adjustments and Asset Reversions
	  	OCT 2004
	52.215-16	  	 Facilities Capital Cost of Money
	  	JUN 2003
	52.215-19	  	 Notification of Ownership Changes
	  	OCT 1997
	52.215-23	  	 Limitations on Pass-Through Charges
	  	OCT 2009
	52.216-7	  	 Allowable Cost And Payment
	  	DEC 2002
	52.219-6	  	 Notice Of Total Small Business Set-Aside
	  	JUN 2003
	52.219-8	  	 Utilization of Small Business Concerns
	  	MAY 2004
	52.219-14	  	 Limitations On Subcontracting
	  	DEC 1996
	52.222-19	  	 Child Labor—Cooperation with Authorities and Remedies
	  	AUG 2009
	52.222-20	  	 Walsh-Healey Public Contracts Act
	  	DEC 1996
	52.222-21	  	 Prohibition Of Segregated Facilities
	  	FEB 1999
	52.222-26	  	 Equal Opportunity
	  	MAR 2007
	52.222-35	  	 Equal Opportunity For Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
	  	SEP 2006
	52.222-36	  	 Affirmative Action For Workers With Disabilities
	  	JUN 1998
	52.222-37	  	 Employment Reports On Special Disabled Veterans, Veterans Of The Vietnam Era, and Other Eligible Veterans
	  	SEP 2006
	52.222-39	  	 Notification of Employee Rights Concerning Payment of Union Dues or Fees
	  	DEC 2004
	52.222-50	  	 Combating Trafficking in Persons
	  	FEB 2009
	52.223-3	  	 Hazardous Material Identification And Material Safety Data
	  	JAN 1997
	52.223-6	  	 Drug-Free Workplace
	  	MAY 2001
	52.223-14	  	 Toxic Chemical Release Reporting
	  	AUG 2003
	52.225-13	  	 Restrictions on Certain Foreign Purchases
	  	JUN 2008

 W9113M-10-C-0057 
  Page 
 19
 of 24 
  

					
	52.227-1	  	 Authorization and Consent
	  	DEC 2007
	52.227-2	  	 Notice And Assistance Regarding Patent And Copyright Infringement
	  	DEC 2007
	52.227-11	  	 Patent Rights—Ownership By The Contractor
	  	DEC 2007
	52.227-14	  	 Rights in Data—General
	  	DEC 2007
	52.228-7	  	 Insurance—Liability To Third Persons
	  	MAR 1996
	52.232-1	  	 Payments
	  	APR 1984
	52.232-17	  	 Interest
	  	OCT 2008
	52.232-20	  	 Limitation Of Cost
	  	APR 1984
	52.232-22	  	 Limitation Of Funds
	  	APR 1984
	52.232-23	  	 Assignment Of Claims
	  	JAN 1986
	52.232-33	  	 Payment by Electronic Funds Transfer—Central Contractor Registration
	  	OCT 2003
	52.233-1	  	 Disputes
	  	JUL 2002
	52.233-3 Alt I	  	 Protest After Award (Aug 1996) - Alternate I
	  	JUN 1985
	52.233-4	  	 Applicable Law for Breach of Contract Claim
	  	OCT 2004
	52.242-1	  	 Notice of Intent to Disallow Costs
	  	APR 1984
	52.242-3	  	 Penalties for Unallowable Costs
	  	MAY 2001
	52.242-4	  	 Certification of Final Indirect Costs
	  	JAN 1997
	52.242-13	  	 Bankruptcy
	  	JUL 1995
	52.242-15 Alt I	  	 Stop-Work Order (Aug 1989) - Alternate I
	  	APR 1984
	52.242-17	  	 Government Delay Of Work
	  	APR 1984
	52.243-2	  	 Changes—Cost-Reimbursement
	  	AUG 1987
	52.243-2 Alt V	  	 Changes—Cost-Reimbursement (Aug 1987) - Alternate V
	  	APR 1984
	52.244-2	  	 Subcontracts
	  	JUN 2007
	52.244-5	  	 Competition In Subcontracting
	  	DEC 1996
	52.244-6	  	 Subcontracts for Commercial Items
	  	AUG 2009
	52.249-6	  	 Termination (Cost Reimbursement)
	  	MAY 2004
	52.249-14	  	 Excusable Delays
	  	APR 1984
	52.253-1	  	 Computer Generated Forms
	  	JAN 1991
	252.203-7000	  	 Requirements Relating to Compensation of Former DoD Officials
	  	JAN 2009
	252.203-7001	  	 Prohibition On Persons Convicted of Fraud or Other Defense-Contract-Related Felonies
	  	DEC 2008
	252.204-7004 Alt A	  	 Central Contractor Registration (52.204-7) Alternate A
	  	SEP 2007
	252.204-7006	  	 Billing Instructions
	  	OCT 2005
	252.204-7008	  	 Export-Controlled Items
	  	APR 2010
	252.205-7000	  	 Provision Of Information To Cooperative Agreement Holders
	  	DEC 1991
	252.209-7004	  	 Subcontracting With Firms That Are Owned or Controlled By The Government of a Terrorist Country
	  	DEC 2006
	252.211-7003	  	 Item Identification and Valuation
	  	AUG 2008
	252.215-7000	  	 Pricing Adjustments
	  	DEC 1991
	252.215-7000	  	 Pricing Adjustments
	  	DEC 1991
	252.215-7004	  	 Excessive Pass-Through Charges
	  	MAY 2008
	252.215-7004	  	 Excessive Pass-Through Charges
	  	MAY 2008
	252.223-7001	  	 Hazard Warning Labels
	  	DEC 1991
	252.225-7004	  	 Report of Contract Performance Outside the United States and Canada—Submission after Award
	  	MAY 2007
	252.225-7006	  	 Quarterly Reporting of Actual Contract Performance Outside the United States
	  	MAY 2007
	252.225-7012	  	 Preference For Certain Domestic Commodities
	  	DEC 2008
	252.227-7039	  	 Patents—Reporting Of Subject Inventions
	  	APR 1990
	252.232-7003	  	 Electronic Submission of Payment Requests and Receiving Reports
	  	MAR 2008
	252.232-7010	  	 Levies on Contract Payments
	  	DEC 2006

 W9113M-10-C-0057 
  Page 
 20
 of 24 
  

					
	252.235-7002	  	 Animal Welfare
	  	DEC 1991
	252.235-7004	  	 Protection of Human Subjects
	  	JUL 2009
	252.243-7002	  	 Requests for Equitable Adjustment
	  	MAR 1998
	252.244-7000	  	 Subcontracts for Commercial Items and Commercial Components (DoD Contracts)
	  	AUG 2009
	252.247-7023	  	 Transportation of Supplies by Sea
	  	MAY 2002
	252.247-7024	  	 Notification Of Transportation Of Supplies By Sea
	  	MAR 2000

 CLAUSES INCORPORATED BY FULL TEXT 

52.216-10              INCENTIVE FEE (MAR 1997) 

(a) General. The Government shall pay the Contractor for performing this contract a fee determined as provided in this contract. 

(b) Target cost and target fee. The target cost and target fee specified in the Schedule are subject to adjustment if the contract is modified in
accordance with paragraph (d) below. 
 (1) “Target cost,” as used in this contract, means the estimated cost of this contract as
initially negotiated, adjusted in accordance with paragraph (d) below. 
 (2) “Target fee,” as used in this contract, means the
fee initially negotiated on the assumption that this contract would be performed for a cost equal to the estimated cost initially negotiated, adjusted in accordance with paragraph (d) below. 

(c) Withholding of payment. Normally, the Government shall pay the fee to the Contractor as specified in the Schedule. However, when the Contracting
Officer considers that performance or cost indicates that the Contractor will not achieve target, the Government shall pay on the basis of an appropriate lesser fee. When the Contractor demonstrates that performance or cost clearly indicates that
the Contractor will earn a fee significantly above the target fee, the Government may, at the sole discretion of the Contracting Officer, pay on the basis of an appropriate higher fee. After payment of [*] percent of the applicable fee, the
Contracting Officer may withhold further payment of fee until a reserve is set aside in an amount that the Contracting Officer considers necessary to protect the Government’s interest. This reserve shall not exceed [*] percent of the applicable
fee or $[*], whichever is less. The Contracting Officer shall release [*] percent of all fee withholds under this contract after receipt of the certified final indirect cost rate proposal covering the year of physical completion of this contract,
provided the Contractor has satisfied all other contract terms and conditions, including the submission of the final patent and royalty reports, and is not delinquent in submitting final vouchers on prior years’ settlements. The Contracting
Officer may release up to [*] percent of the fee withholds under this contract based on the Contractor’s past performance related to the submission and settlement of final indirect cost rate proposals. 

(d) Equitable adjustments. When the work under this contract is increased or decreased by a modification to this contract or when any equitable
adjustment in the target cost is authorized under any other clause, equitable adjustments in the target cost, target fee, minimum fee, and maximum fee, as appropriate, shall be stated in a supplemental agreement to this contract. 

(e) Fee payable. (1) The fee payable under this contract shall be the target fee increased by [*] [Contracting Officer insert Contractor’s
participation] cents for every dollar that the total allowable cost is less than the target cost or decreased by [*], [Contracting Officer insert Contractor’s participation] cents for every dollar that the total allowable cost exceeds the
target cost. In no event shall the fee be greater than [*][Contracting Officer insert percentage] percent or less than ...... [*] [Contracting Officer insert percentage] percent of the target cost. 

(2) The fee shall be subject to adjustment, to the extent provided in paragraph (d) above, and within the minimum and maximum fee limitations in
subparagraph (1) above, when the total allowable cost is increased or decreased as a consequence of (i) payments made under assignments or (ii) claims excepted from the release as required by paragraph (h)(2) of the Allowable Cost and
Payment clause. 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 21
 of 24 
  

 (3) If this contract is terminated in its entirety, the portion of the target fee payable shall not be
subject to an increase or decrease as provided in this paragraph. The termination shall be accomplished in accordance with other applicable clauses of this contract. 
 (4) For the purpose of fee adjustment, “total allowable cost” shall not include allowable costs arising out of— 
 (i) Any of the causes covered by the Excusable Delays clause to the extent that they are beyond the control and without the fault or negligence of the Contractor or any subcontractor; 

(ii) The taking effect, after negotiating the target cost, of a statute, court decision, written ruling, or regulation that results in the
Contractor’s being required to pay or bear the burden of any tax or duty or rate increase in a tax or duty; 
 (iii) Any direct cost
attributed to the Contractor’s involvement in litigation as required by the Contracting Officer pursuant to a clause of this contract, including furnishing evidence and information requested pursuant to the Notice and Assistance Regarding
Patent and Copyright Infringement clause; 
 (iv) The purchase and maintenance of additional insurance not in the target cost and required by
the Contracting Officer, or claims for reimbursement for liabilities to third persons pursuant to the Insurance Liability to Third Persons clause; 
 (v) Any claim, loss, or damage resulting from a risk for which the Contractor has been relieved of liability by the Government Property clause; or 
 (vi) Any claim, loss, or damage resulting from a risk defined in the contract as unusually hazardous or as a nuclear risk and against which the Government has expressly agreed to indemnify the Contractor.

 (5) All other allowable costs are included in “total allowable cost” for fee adjustment in accordance with this paragraph (e),
unless otherwise specifically provided in this contract. 
 (f) Contract modification. The total allowable cost and the adjusted fee determined
as provided in this clause shall be evidenced by a modification to this contract signed by the Contractor and Contracting Officer. 
 (g)
Inconsistencies. In the event of any language inconsistencies between this clause and provisioning documents or Government options under this contract, compensation for spare parts or other supplies and services ordered under such documents shall be
determined in accordance with this clause. 
 (End of clause) 
 52.217-7    OPTION FOR INCREASED QUANTITY—SEPARATELY PRICED LINE ITEM (MAR 1989) 
 The Government may require the delivery of the numbered line item, identified in the Schedule as an option item, in the quantity and at the price stated in the Schedule. The Contracting Officer may
exercise the option by written notice to the Contractor within [*] days. 
 (End of clause) 

52.219-28    POST-AWARD SMALL BUSINESS PROGRAM REREPRESENTATION (APR 2009) 

  

*Confidential Treatment Requested. 

 W9113M-10-C-0057 
  Page 
 22
 of 24 
  

 (a) Definitions. As used in this clause— 
 Long-term contract means a contract of more than five years in duration, including options. However, the term does not include contracts that exceed five years in duration because the period of
performance has been extended for a cumulative period not to exceed six months under the clause at 52.217-8, Option to Extend Services, or other appropriate authority. 
 Small business concern means a concern, including its affiliates, that is independently owned and operated, not dominant in the field of operation in which it is bidding on Government contracts, and
qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (c) of this clause. Such a concern is not dominant in its field of operation” when it does not exercise a controlling or major influence
on a national basis in a kind of business activity in which a number of business concerns are primarily engaged. In determining whether dominance exists, consideration shall be given to all appropriate factors, including volume of business, number
of employees, financial resources, competitive status or position, ownership or control of materials, processes, patents, license agreements, facilities, sales territory, and nature of business activity. 

(b) If the Contractor represented that it was a small business concern prior to award of this contract, the Contractor shall rerepresent its size status
according to paragraph (e) of this clause or, if applicable, paragraph (g) of this clause, upon the occurrence of any of the following: 
 (1) Within 30 days after execution of a novation agreement or within 30 days after modification of the contract to include this clause, if the novation agreement was executed prior to inclusion of this
clause in the contract. 
 (2) Within 30 days after a merger or acquisition that does not require a novation or within 30 days after
modification of the contract to include this clause, if the merger or acquisition occurred prior to inclusion of this clause in the contract. 

(3) For long-term contracts— 
 (i) Within
60 to 120 days prior to the end of the fifth year of the contract; and 
 (ii) Within 60 to 120 days prior to the date specified in the contract
for exercising any option thereafter. 
 (c) The Contractor shall rerepresent its size status in accordance with the size standard in effect at
the time of this rerepresentation that corresponds to the North American Industry Classification System (NAICS) code assigned to this contract. The small business size standard corresponding to this NAICS code can be found at
http://www.sba.gov/services/contractingopportunities/sizestandardstopics/. 
 (d) The small business size standard for a Contractor providing a
product which it does not manufacture itself, for a contract other than a construction or service contract, is 500 employees. 
 (e) Except as
provided in paragraph (g) of this clause, the Contractor shall make the rerepresentation required by paragraph (b) of this clause by validating or updating all its representations in the Online Representations and Certifications
Application and its data in the Central Contractor Registration, as necessary, to ensure that they reflect the Contractor’s current status. The Contractor shall notify the contracting office in writing within the timeframes specified in
paragraph (b) of this clause that the data have been validated or updated, and provide the date of the validation or update. 
 (f) If the
Contractor represented that it was other than a small business concern prior to award of this contract, the Contractor may, but is not required to, take the actions required by paragraphs (e) or (g) of this clause. 

(g) If the Contractor does not have representations and certifications in ORCA, or does not have a representation in ORCA for the NAICS code applicable
to this contract, the Contractor is required to complete the following rerepresentation and submit it to the contracting office, along with the contract number and the date on which the rerepresentation was completed: 

The Contractor represents that it (    ) is, (    ) is not a small business concern under NAICS Code 541711-
assigned to contract number. 

 W9113M-10-C-0057 
  Page 
 23
 of 24 
  

 (Contractor to sign and date and insert authorized signer’s name and title). 

(End of clause) 

52.252-2    CLAUSES INCORPORATED BY REFERENCE (FEB 1998) 
 This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available.
Also, the full text of a clause may be accessed electronically at this/these address(es): 
 http://farsite.hill.af.mil 

(End of clause) 

252.204-7000    DISCLOSURE OF INFORMATION (DEC 1991) 
 (a) The Contractor shall not release to anyone outside the Contractor’s organization any unclassified information, regardless of medium (e.g., film, tape, document), pertaining to any part of this
contract or any program related to this contract, unless— 
 (1) The Contracting Officer has given prior written approval; or 

(2) The information is otherwise in the public domain before the date of release. 
 (b) Requests for approval shall identify the specific information to be released, the medium to be used, and the purpose for the release. The Contractor shall submit its request to the Contracting Officer
at least 45 days before the proposed date for release. 
 (c) The Contractor agrees to include a similar requirement in each subcontract under
this contract. Subcontractors shall submit requests for authorization to release through the prime contractor to the Contracting Officer. 

(End of clause) 

252.235-7010    Acknowledgment of Support and Disclaimer. (MAY 1995) 
 (a) The Contractor shall include an acknowledgment of the Government’s support in the publication of any material based on or developed under this contract, stated in the following terms: This
material is based upon work supported by the US Army Space and Missile Defense Command under Contract No. [Insert upon award] 
 (b) All
material, except scientific articles or papers published in scientific journals, must, in addition to any notices or disclaimers by the Contractor, also contain the following disclaimer: Any opinions, findings and conclusions or recommendations
expressed in this material are those of the author(s) and do not necessarily reflect the views of the [name of contracting agency(ies)]. 

 W9113M-10-C-0057 
  Page 
 24
 of 24 
  

 Section J - List of Documents, Exhibits and Other Attachments 

SECTION J 
 LIST OF ATTACHMENTS

  

											
	Attachment No.	  	Description	  	Date	 	  	Number of Pages	  	 
	1	  	Contractor’s Statement of Work	  	 	3/22/10	  	  	20	  	

 Exhibit No. 
  

			
	A001	 	Contract Work Breakdown Structure (CWBS)
	A002	 	Contractor’s Progress, Status, & Management Report
	A003	 	Contract Funds Status Report, DD Form 1586
	A004	 	Integrated Master Schedule
	A005	 	Contract Performance Report
	A006	 	In Process ReviewLicense Agreement

 Exhibit 4.17 

 

	 	*	Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

 LICENSE AGREEMENT 
 THIS AGREEMENT is dated effective July 1, 1998, 
 AMONG: 

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its
administrative offices at 2075 Wesbrook Mall, in the City of Vancouver, in the Province of British Columbia, V6T 1W5, 
 (the
“University”) 
 AND: 
 INEX PHARMACEUTICALS CORPORATION, a corporation duly incorporated under the laws of the Province of British Columbia and having an office at 100—8900 Glenlyon Parkway , in the City of Burnaby,
in the Province of British Columbia, V5J 5J8 
 (the “Licensee”) 

WHEREAS: 
 A.
Dr. Pieter R. Cullis, Professor, Department of Biochemistry and Molecular Biology at the University has been engaged in research during the course of which the University has invented, developed and/or acquired certain technology which is
subject to the Licensee’s option pursuant to a Research Agreement dated February 1, 1993 and a Collaborative Research Agreement dated effective January 1, 1999 and successor agreements thereto; 

B. Pursuant to research agreements between the University and the Licensee, the University has been engaged in research during the course of which it has
invented, developed and/or acquired certain technology relating to liposome drug delivery technologies; 
 C. On or about July 1, 1998, the
University and the Licensee entered into a License Agreement relating to certain liposome drug delivery technologies, (the “1998 License”). On or about March 16, 1999, the Licensee and Esperion Therapeutics, Inc.
(“Esperion”) entered into a sublicense agreement whereby certain technology licensed by the University to the Licensee under the 1998 License relating to liposome compositions and methods for the treatment of atherosclerosis
(the “UBC 94-049 Technology”), was sublicensed by the Licensee to Esperion (the “Esperion Sublicense”); 
 D. The University and the Licensee have now agreed to consolidate in one License Agreement: 

  -
 2
 - 
  

	 	(i)	all of the technologies invented, developed and/or acquired pursuant to the research agreements between the University and the Licensee since entering into the 1998
License, and in respect of which the Licensee has validly exercised its option to obtain a License, (which technologies have been listed and identified in Part I of the attached Schedule “A”); and 

 

	 	(ii)	all of the technologies licensed by the University to the Licensee under the terms of the 1998 License (which technologies have been listed and identified in Part II of
the attached Schedule “A”), excepting only the UBC 94-049 Technology sublicensed by the Licensee to Esperion under the Esperion Sublicense; 

 E. In order to effect the consolidation of the new technologies and the technologies licensed under the 1998 License, the University and the Licensee have agreed to amend the 1998 License so as to delete
and remove from the 1998 License all of the technologies licensed by the University to the Licensee under the terms of the 1998 License (with the exception only of the UBC 94-049 Technology sublicensed by the Licensee to Esperion under the Esperion
Sublicense) and to grant a new license with respect to all of the remaining technologies to the Licensee under the terms of this Agreement; 

NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the premises and of the mutual covenants herein set forth, the parties hereto
have covenanted and agreed as follows: 
 1.0 DEFINITIONS: 
 1.1 In this Agreement, unless a contrary intention appears, the following words and phrases shall mean: 
  

	 	(a)	“Accounting”: an accounting statement setting out in detail how the amount of Revenue and Sublicensing Revenue received by the Licensee and its
Affiliates and sublicensees is determined. 

  

	 	(b)	“Affiliate” or “Affiliated Company” or “Affiliated Companies”: with respect to any specified person, any other person
that directly controls, is controlled by, or is under common control with, such specified person. For the purposes of this Article 1.1(b), “control” shall mean: 

 

	 	(i)	in the case of corporate entities, the direct or indirect ownership of at least 50% of the stock or participating shares entitled to vote in the general meeting of
shareholders, and 

  

	 	(ii)	in the case of a partnership or other legal entity, ownership of at least 50% interest in the income or at least a 50% interest in the power to direct the management or
policies of such entity. 

  

	 	    	For the purposes of this Agreement, the parties agree that Protiva Biotherapeutics Inc. shall not be an Affiliate of the Licensee. 

 

	 	(c)	“Collaborative Research Agreement”: the Collaborative Research Agreement between the parties dated effective January 1, 1999 and successor
agreements thereto. 

  -
 3
 - 
  

	 	(d)	“Confidential Information”: any part of the Information which is furnished by either party to the other and designated at that time as confidential,
whether orally or in writing but excluding any part of the Information: 

  

	 	(i)	possessed by the Recipient prior to receipt from the Discloser, as evidenced by the Recipient’s business records; 

 

	 	(ii)	published or available to the general public otherwise than through a breach of this Agreement; 

 

	 	(iii)	obtained by the Recipient from a third party with a valid right to disclose it, provided that said third party is not known by the Recipient to be under a
confidentiality obligation to the Discloser ; or 

  

	 	(iv)	independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the Confidential Information as evidenced by the
Recipient’s business records. 

  

	 	(e)	“Date of Commencement” or “Commencement Date”: this Agreement will be deemed to have come into force on the Date of Commencement which
shall be July 1, 1998, and shall be read and construed accordingly. 

  

	 	(f)	“Discloser”: means a party to this Agreement providing its Confidential Information to the other party as Recipient. 

 

	 	(g)	“Effective Date of Termination”: the date on which this Agreement is terminated pursuant to Article 17. 

 

	 	(h)	“Information”: any and all Technology, the terms and conditions of this Agreement, and any and all oral, written, electronic or other communications
and other information disclosed or provided by the parties including any and all analyses or conclusions drawn or derived therefrom regarding this Agreement and information developed or disclosed hereunder, or any party’s raw materials,
processes, formulations, analytical procedures, methodologies, products, samples and specimens or functions. 

  

	 	(i)	“Patent(s)”: all Valid Claims of the following intellectual property: 

 

	 	(i)	the Canadian, United States and foreign patents and/or patent applications listed in Schedule “A”; 

 

	 	(ii)	Canadian, United States and foreign patents issued from the applications listed in Schedule “A” and from any and all divisionals and continuations of
these applications; 

  

	 	(iii)	claims of Canadian, United States and foreign continuation-in-part applications and of the resulting patents, which are directed to subject matter specifically
described in the Canadian, United States, and foreign applications listed in Schedule “A” 

  

	 	(iv)	claims of all foreign patent applications, and of the resulting patents, which are directed to subject matter specifically described in the Canadian and United States
patents and/or patent applications described in (i), (ii) or (iii) above; and 

  -
 4
 - 
  

	 	(v)	any reissues of United States, Canadian or foreign patents described in (i), (ii), (iii) or (iv) above. 

 

	 	(j)	“Product(s)”: goods, the manufacture, use or sale of which would, but for the license granted herein, infringe a Valid Claim of one or more of the
Patent(s). 

  

	 	(k)	“Recipient”: means a party to this Agreement receiving Confidential Information of the other party as Discloser. 

 

	 	(l)	“Revenue”: all revenues, receipts, monies, and the fair market value of all other consideration collected or received by the Licensee or its Affiliates
from a sublicensee or other third party whether by way of cash or credit or any barter, benefit, advantage, or concession (but not including Sublicensing Revenue) from the marketing, manufacturing, sale, distribution, or use, of the Technology
and/or any Products in any or all parts of the world where the Licensee is permitted by law and this Agreement to market, manufacture, sell, distribute or use the Technology and/or any Products, in such national jurisdictions where a Valid Claim
subsists, on a country by country basis, less the following deductions to the extent included in the amounts invoiced and thereafter actually allowed and taken: 

 

	 	(i)	credit, allowances or refunds given on account of returned goods, 

  

	 	(ii)	transportation charges invoiced separately and actually charged to third parties, 

 

	 	(iii)	taxes, duties and customs on all sales of Products, 

  

	 	(iv)	agents’ commissions paid by the Licensee for the sale of Products, and 

 

	 	(v)	bona fide special rebates provided by the Licensee for Products purchased by third parties. 

Where any Revenue is derived from a country other than Canada it shall be converted to the equivalent in Canadian dollars on the date the
Licensee is deemed to have received such Revenue pursuant to the terms hereof at the rate of exchange set by the Royal Bank of Canada for buying such currency. The amount of Canadian dollars pursuant to such conversion shall be included in the
Revenue. 
  

	 	(m)	“Royalty Due Dates”: the last working day of March, June, September and December of each and every year during which this Agreement remains in full
force and effect. 

  

	 	(n)	 “Sublicensing Revenue”: all revenues, receipts, monies, milestone payments and research fees (in respect of either milestone payments
or research fees, only to the extent that same are in excess of reimbursement for the direct costs of research and development or pursuit of regulatory approval undertaken by the Licensee or its Affiliates, pursuant to a written research or
development plan), 

  -
 5
 - 
  

	 	 
payments, royalties, license fees and the fair market value of all other consideration collected or received by the Licensee or its Affiliates whether by way of cash, or credit or any barter,
benefit, advantage, or concession pursuant to each sublicense agreement relating to Valid Claims which form a part of the Technology and/or any Products (but not including Revenue). Where any Sublicensing Revenue is derived from a country other than
Canada it shall be converted to the equivalent in Canadian dollars on the date the Licensee is deemed to have received such Sublicensing Revenue pursuant to the terms hereof at the rate of exchange set by the Royal Bank of Canada for buying such
currency. The amount of Canadian dollars pursuant to such conversion shall be included in the Sublicensing Revenue. 

  

	 	(o)	“Technology”: the Patent(s) and any and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, being invented,
developed and/or acquired by the University solely or jointly with the Licensee relating to the Patent(s) as listed in Schedule “A” hereto, as amended from time to time, including, without limitation, all research, data,
specifications, instructions, manuals, papers or other materials of any nature whatsoever, whether written or otherwise, relating to same. 

  

	 	(p)	“UBC Trade-marks”: any mark, trade-mark, service mark, logo, insignia, seal, design, symbol, or device used by the University in any manner whatsoever.

  

	 	(q)	“Valid Claim”: shall mean either: 

  

	 	(i)	a claim of an issued and unexpired patent included within the Technology, which has not been held unenforceable, unpatentable or invalid by a court or other
governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or 

  

	 	(ii)	a claim in a hypothetical issued patent corresponding to a pending claim in a patent application within the Technology, provided that if such pending claim has not
issued as a claim of an issued patent within the Technology within [*] years after the filing date of such patent application, such pending claim shall not be a Valid Claim for purposes of this Agreement. In the event that a claim of an issued
patent within the Technology is held by a court or other governmental agency of competent jurisdiction to be unenforceable, unpatentable or invalid, and such holding is reversed on appeal by a higher court or agency of competition jurisdiction, such
claim shall be reinstated as a Valid Claim hereunder. 

 2.0 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY: 

2.1 The parties hereto hereby acknowledge and agree that the University owns any and all right, title and interest in and to the Technology. 

2.2 The Licensee shall, at the request of the University, enter into such further agreements and execute any and all documents as may be required to
ensure that ownership of the Technology remains with the University. 
  
 *Confidential Treatment Requested. 

  -
 6
 - 
  

 2.3 On the last working day of June of each and every year during which this Agreement remains in full
force and effect, the Licensee shall deliver in writing the details of any Patents filed during the previous twelve month period. 
 3.0
GRANT OF LICENSE : 
 3.1 In consideration of the Royalty payments reserved herein, and the covenants on the part of the Licensee
contained herein, the University hereby grants to the Licensee an exclusive worldwide license to use and sublicense the Technology and to manufacture, have made, distribute, import, use and sell Products on the terms and conditions hereinafter set
forth during the term of this Agreement. 
 3.2 The Licensee shall not cross-license the Technology without the prior written consent of the
University. 
 3.3 Notwithstanding Article 3.1 herein, the parties acknowledge and agree that the University may use the Technology without
charge in any manner whatsoever for non-commercial research, scholarly publication, educational or other non-commercial use. 
 4.0
SUBLICENSING: 
 4.1 The Licensee shall have the right to grant sublicenses to third parties with respect to the Technology with the
prior written consent of the University, not to be unreasonably withheld. 
 4.2 The Licensee shall have the right to grant sublicenses to
Affiliates with respect to the Technology without the prior written consent of the University, provided that: 
  

	 	(a)	the Licensee will cause the Affiliate so sublicensed to perform the terms of this Agreement as if such Affiliate were the Licensee hereunder; and

  

	 	(b)	any Affiliate so sublicensed shall unconditionally, absolutely and irrevocably covenant and agree with the University as primary obligor, to adopt as its own
obligations every obligation of the Licensee contained or set forth in this Agreement, including without limitation, the covenants in this Agreement to pay any amounts due to the University under the terms of this Agreement. The obligations and
liabilities of such Affiliate and the Licensee under this Agreement shall be joint and several and the University shall not be obliged to seek recourse against an Affiliate before enforcing its rights against the Licensee. For greater certainty it
is hereby confirmed that any default or breach by an Affiliate of any term of this Agreement will also constitute a default by the Licensee under this Agreement. 

 4.3 The Licensee will furnish the University with a copy of each sublicense granted within [*] days after execution. 
 4.4 Any sublicense (including any sublicense granted to an Affiliate) granted by the Licensee shall contain covenants by the sublicensee to observe and perform similar terms and conditions to those in
this Agreement, including, without limitation, a restriction on the grant of further sublicenses without the University’s consent. 
  

*Confidential Treatment Requested. 

  -
 7
 - 
  

 4.5 On granting approval to any sublicense, pursuant to Article 4.1, the University will upon request by
the approved sublicensee, provide such sublicensee with a letter confirming that if the University: 
  

	 	(a)	gives notice of default to the Licensee pursuant to Article 17.3 of this Agreement, or 

 

	 	(b)	takes any other action pursuant to Articles 17.1 or 17.2 of this Agreement to terminate this Agreement, 

then, prior to any termination of this Agreement, the University will give such sublicensee written notice of such default or intention to terminate this
Agreement, and in the event of any breach or default by the Licensee, which may be cured pursuant to Article 17.3, will for [*] days from the date of such notice to the sublicensee, give the sublicensee the opportunity to cure such default or breach
on the terms provided in Article 17.3 of this Agreement, mutatis mutandis. If this Agreement is terminated, and provided that the sublicense between the Licensee and the sublicensee is in good standing at such time, the University will then
enter into good faith negotiations with such sublicensee for the grant to the sublicensee of a new license substantially on the same terms and conditions as are contained in this Agreement. 
 5.0 ROYALTIES AND CONSIDERATION: 
 5.1 The Licensee shall pay to the University a
royalty (the “Royalty”): 
  

	 	(a)	on all Revenue calculated in accordance with the percentages set out in the “UBC Royalty” Column of Schedule “A”;

  

	 	(b)	on all Sublicensing Revenue, calculated in accordance with the percentages set out in the “UBC Sublicense Royalty” Column of Schedule
“A”. 

 All subject to the limitation that in no event will the Royalties payable on Sublicensing Revenue
and Revenue from any sublicensee exceed the amount of Royalties that would be payable on Revenues if the Technology and/or Products had been marketed, manufactured, sold, distributed or used by the Licensee instead of such sublicensee. 

If Schedule “A” is amended at any time after the Commencement Date to add any new Technology, patent or other intellectual
property, then the Royalty on Revenue or Sublicensing Revenue shall be calculated for any such new Technology, patent or other intellectual property in accordance with the provisions set out in Schedule “B”. 

5.2 The University and the Licensee understand and recognize that there are many Patents comprising the Technology and consequently it is foreseeable
that a Product developed by the Licensee may be subject to multiple royalty obligations as a result of more than one patent contributing to the development of such Product. The University and the Licensee agree that the Royalty payable by the
Licensee to the University shall be adjusted as follows: 
  

	 	(a)	if more than one Patent licensed under this Agreement is required in respect of a Product, then the Royalty applicable to any such specific Product pursuant to Article
5.1 hereof may be reduced such that there shall only be one Royalty payable on such Product and that Royalty shall be the Royalty for one of the Patents used (determined in accordance with Article 5.1 and Schedule “B”) which is most
favourable to the University; 

  

*Confidential Treatment Requested. 

  -
 8
 - 
  

	 	(b)	if it is reasonably commercially necessary for a Product to be subject to royalty obligations to one or more third parties, or if the Licensee licenses or owes a
royalty in respect of one or more patents from one or more third parties, to be used in combination with the Patents licensed hereunder, then the Royalties set out in Article 5.1 shall be adjusted by apportioning the relative value between the
Technology and said third party patent(s) by multiplying the Royalty by the formula a/(a+b) where “a” is the value of the Patent licensed under this Agreement, and “b” is the value of the
third party patent(s) provided that “b” shall never be fixed at a value higher than “a”. Values “a” and “b” shall be determined on the basis of the values of each patent when used
separately and not used in combination with each other. If the parties are unable to come to agreement on said respective values, the issue will be determined by arbitration pursuant to Article 14. For greater certainty, notwithstanding anything in
this Article 5.2(b), the final Royalty payable by the Licensee to the University shall not be less than [*] of the Royalties determined in accordance with Article 5.1. 

 5.3 The Royalty shall become due and payable within [*] days of each respective Royalty Due Date and shall be calculated with respect to the Revenue and the Sublicensing Revenue in the three month period
immediately preceding the applicable Royalty Due Date. 
 5.4 All payments of Royalties made by the Licensee to the University hereunder shall
be made in Canadian dollars without any reduction or deduction of any nature or kind whatsoever, except as may be prescribed by law. 
 5.5
Revenue shall be deemed to have been received by the Licensee or any Affiliate when actually received, provided that diligent efforts short of commencing legal action are made to collect same. Sublicensing Revenue shall be deemed to have been
received by the Licensee or any Affiliate with respect to each of their sublicensees when such consideration is actually received. 
 5.6 Any
transaction, disposition, or other dealing involving the Technology or any part thereof between the Licensee and another person that is not made at fair market value shall be deemed to have been made at fair market value, and the fair market value
of that transaction, disposition, or other dealing shall be deemed to be part of the Revenue (or the Sublicensing Revenue, as the case may be) and shall be included in the calculation of Royalties under this Agreement. 

5.7 Revenue shall not include and no Royalties will be payable on Products used for research and development of the Products or the Technology for which
the Licensee does not receive consideration, such as but not limited to dispositions for clinical trials, marketing, research use and compassionate use or for other similar uses. 
 5.8 Sublicensing Revenue shall not include and no Royalties will be payable on: 
  

	 	(a)	loans to the Licensee by a sublicensee relating to the Technology except to the extent that the interest charged for same is less than fair market value (in which case
such difference shall be Sublicensing Revenue) or to the extent that the principal of same is forgiven (in which case such forgiven amount shall be Sublicensing Revenue); or 

 

	 	(b)	investments in the Licensee by a sublicensee relating to the Technology except to the extent that such investments are made at greater than fair market value (in

  
 *Confidential Treatment Requested.

  -
 9
 - 
  

	 	 
which case such premium shall be Sublicensing Revenue). For the purposes of this subsection, if the shares are not listed on any stock exchange, the fair market value shall be based on the price
at which shares have been issued to investors (who are not industry-related strategic investors or collaborative research partners) in the then most recent bona fide arm’s length private placement financing completed within the preceding [*]
months having gross proceeds of at least [*]. If no such private placement financing has been completed, the parties hereto shall appoint a mutually acceptable person as an independent evaluator and if the parties cannot agree on an evaluator, the
appointing authority shall be the British Columbia International Commercial Arbitration Centre. 

 5.9 If at any time, a third
party in any country shall, under the right of a compulsory license granted or ordered to be granted by a competent governmental authority, manufacture, use or sell any Product with respect to which Royalties would be payable pursuant to this
Agreement, then the Licensee may reduce the Royalty on sales in such country of such Product to an amount no greater than the amount payable by said third party to the Licensee as consideration for the compulsory license. 

5.10 No Royalty shall be payable on the sales of Products between the Licensee and its Affiliates, provided that Royalties shall be payable on all
Revenue received by the Licensee or its Affiliate(s) from any subsequent sale of such Products to a sublicensee or to a third party. 
 5.11 No
Royalties shall be payable on Sublicensing Revenue paid to the Licensee from its Affiliates, but Royalties shall be payable on the Sublicensing Revenue of the Licensee’s Affiliates from a third party. 

5.12 If, at any time, legal restrictions prevent the prompt remittance of part or all of Royalties with respect to any country where Revenue or
Sublicensing Revenue is generated, the Licensee or its Affiliates or sublicensees shall have the right and option, on consultation with the University, to make such payments by depositing the amount thereof in local currency for the benefit of the
University in a bank or depository in such country. 
 5.13 In further consideration for the license granted hereunder, the Licensee shall pay
to the University, in addition to all other amounts due under this Agreement, an annual maintenance fee of [*] payable on or before January 2 of each year during which this Agreement remains in full force and effect, commencing on
January 2, 2002 (the “Annual Maintenance Fee”). Neither all nor any part of the Annual Maintenance Fee paid shall be refundable to the Licensee under any circumstances. 

6.0 PATENTS: 
 6.1 The Licensee
shall pay all costs of prosecuting and maintaining the Patents. 
 6.2 The Licensee shall have the right, with reasonable input from the
University, to identify any process, use or products arising out of the Technology that may be patentable and shall take all reasonable steps to apply for a patent in the name of the University provided that the Licensee pays all costs of applying
for, registering, and maintaining the patent in those jurisdictions in which the Licensee determines that a Patent is required. 
  

*Confidential Treatment Requested. 

  -
 10
 - 
  

 6.3 On the issuance of a patent for the Technology the Licensee shall have the right to become, and
shall become the licensee of the same all pursuant to the terms contained herein. 
 6.4 For the purposes of this Article 6.4,
“Improvements” means, in respect of any Patents: (i) any and all patents and any and all patent applications that claim priority to such Patents (whether complete or incomplete or whether filed or unfiled) including, but not
limited to, provisional, non-provisional, continuations and continuations-in-part, and divisional patent applications and registrations in any jurisdiction world-wide; and (ii) any and all inventions arising from such patents or patent
applications whether patented or not. To the extent possible and unless precluded by any present or future agreement of the Licensee or its sublicensees, any Improvements made: 

 

	 	(a)	by the Licensee, whether solely or jointly with any person other than a sublicensee; 

 

	 	(b)	by a sublicensee, whether solely or jointly with any person other than the Licensee; or 

 

	 	(c)	jointly by the Licensee and a sublicensee 

shall be solely owned by the University, and the Licensee and/or its sublicensees shall assign or cause to be assigned to the University all right, title
and interest in and to such Improvements. Such Improvements shall be added to Schedule “A”. 
 6.5 The Licensee shall advise
the University in writing of all actions which it undertakes concerning the application and maintenance of the Patents, and shall provide copies of the substantive correspondence and documents which it sends or receives in connection therewith.

 6.6 Should the Licensee: 
  

	 	(a)	discontinue pursuing one or more patent applications, patent protection or patent maintenance in relation to the Patent(s) or any continuation, continuation in-part,
division, reissue, re-examination or extension thereof; or 

  

	 	(b)	not pursue patent protection in relation to the Patent(s) in any specific jurisdiction; or 

 

	 	(c)	discontinue or not pursue patent protection in relation to any further process, use or products arising out of the Technology in any jurisdiction;

 then the Licensee shall provide the University with notice of its decision to discontinue or not to pursue such patent
protection in sufficient time, such time not to be less than [*] days for the University to file a Patent application or continue pursuing an existing Patent application at the University’s own expense. 

6.7 If the Licensee discontinues or does not pursue one or more patent applications, patent protection, or patent maintenance, in relation to the
Patent(s) as described in Article 6.6(a), this license shall be terminated with respect to such patent or patent application pursuant to the provisions of Article 17 hereof. If the Licensee discontinues or does not pursue patent applications, patent
protection or patent maintenance in relation to one or more Patents (the 
  
 *Confidential Treatment Requested. 

  -
 11
 - 
  

 
“Discontinued Patent”), provided that the University diligently pursues such Discontinued Patent application, or maintains any existing registration for the Discontinued Patent,
the Licensee shall not have the right to use the Technology claimed in any such Patent(s) and/or Patent applications and Schedule “A” will be deemed to be amended to exclude such Patent(s) and/or Patent applications from the
grant of license contained herein. 
 6.8 For the purposes of greater clarity, the parties agree that should the Licensee decide not to pursue
patent protection in relation to the Patents in a specific jurisdiction for reasonable commercial reasons, this shall not invoke the provisions of Article 6.7. 
 7.0 DISCLAIMER OF WARRANTY: 
 7.1 Except as expressly set out in this Agreement, the
University makes no representations, conditions, or warranties, either express or implied, with respect to the Technology or the Products. Without limiting the generality of the foregoing, the University specifically disclaims any implied warranty,
condition, or representation that the Technology or the Products: 
  

	 	(a)	shall correspond with a particular description; 

  

	 	(b)	are of merchantable quality; 

  

	 	(c)	are fit for a particular purpose; or 

  

	 	(d)	are durable for a reasonable period of time. 

The University shall not be liable for any loss, whether direct, consequential, incidental, or special which the Licensee suffers arising from any
defect, error, fault, or failure to perform with respect to the Technology or Products, even if the University has been advised of the possibility of such defect, error, fault, or failure. The Licensee acknowledges that it has been advised by the
University to undertake its own due diligence with respect to the Technology. 
 7.2 The parties acknowledge and agree that the International
Sale of Goods Act and the United Nations Convention on Contracts for the International Sale of Goods have no application to this Agreement. 

7.3 Except as expressly set out in this Agreement, nothing in this Agreement shall be construed as: 

 

	 	(a)	a warranty or representation by the University as to title to the Technology or that anything made, used, sold or otherwise disposed of under the license granted in
this Agreement is or will be free from infringement of patents, copyrights, trade-marks, industrial design or other intellectual property rights, 

  

	 	(b)	an obligation by the University to bring or prosecute or defend actions or suits against third parties for infringement of patents, copyrights, trade-marks, industrial
designs or other intellectual property or contractual rights, or 

  

	 	(c)	the conferring by the University of the right to use in advertising or publicity the name of the University or UBC Trade-marks. 

7.4 [*] 
  

*Confidential Treatment Requested. 

  -
 12
 - 
  

 7.5 Notwithstanding Article 7.3, in the event of an alleged infringement by a third party of the
Technology or any right with respect to the Technology, or any complaint by the Licensee alleging any infringement by a third party with respect to the Technology or any right with respect to the Technology, the Licensee shall have, upon receiving
the prior written consent of the University, not to be unreasonably withheld or delayed, the right to prosecute such litigation. Provided that it has first granted such consent, not to be unreasonably withheld or delayed, the University agrees to
co-operate reasonably to the extent of executing all necessary documents and to vest in the Licensee the right to institute any such suits, so long as all the direct or indirect costs and expenses of bringing and conducting any such litigation or
settlement shall be borne by the Licensee and in such event all recoveries shall enure to the Licensee. In the event of any litigation: 
  

	 	(a)	the Licensee shall keep the University fully informed of the actions and positions taken or proposed to be taken by the Licensee (on behalf of itself or a sublicensee)
and actions and positions taken by all other parties to such litigation; 

  

	 	(b)	[*] 

  

	 	(c)	the University may elect to participate formally in the litigation to the extent that the court may permit, but any additional expenses generated by such formal
participation shall be paid by the University (subject to the possibility of recovery of some or all of such additional expenses from such other parties to the litigation); 

 

	 	(d)	the Licensee may hold and accrue any Royalties payable by the Licensee to the University from the date an action claiming invalidity of a Patent or Patents is rendered
by a party to such litigation, provided, however, thereafter the Licensee shall continue to account to the University during such period of accrual and promptly, upon termination of such suit by settlement or by unappealable or unappealed decision
of a court of competent jurisdiction, shall pay accrued Royalties to the University after the deduction of any applicable credits, if as a result of termination of such suit, the validity of the Patent or Patents at issue in said suit, and the scope
of such Patent(s), is not changed. If as a result of such suit it is adjudged that such Patent(s) is not valid, or that the valid scope of such Patent(s) no longer reads on a Product, the Licensee may by written notice terminate this Agreement in
respect to such Patent(s) or in the sole discretion of the Licensee, may maintain the License in full force and effect, except that the Licensee shall no longer be liable for the payment of Royalties in respect of such Patent(s).

 7.6 In the event of an alleged infringement of the Technology or any third party use of the Technology which is Confidential
Information, the Licensee and the University agree that they shall reasonably cooperate to enjoin such third party’s use of the Technology. 
 7.7 If any complaint alleging infringement or violation of any patent or other proprietary rights is made against the Licensee (or a sublicensee of the Licensee) with respect to the manufacture, use or
sale of a Product, the following procedure shall be adopted: 
  

	 	(a)	the Licensee shall promptly notify the University upon receipt of any such complaint and shall keep the University fully informed of the actions and positions taken by
the complainant and taken or proposed to be taken by the Licensee (on behalf of itself or a sublicensee), 

  

*Confidential Treatment Requested. 

  -
 13
 - 
  

	 	(b)	except as provided for in Article Error! Reference source not found., all costs and expenses incurred by the Licensee (or any sublicensee of the Licensee) in
investigating, resisting, litigating and settling such a complaint, including the payment of any award of damages and/or costs to any third party, shall be paid by the Licensee (or any sublicensee of the Licensee, as the case may be),

  

	 	(c)	[*] 

  

	 	(d)	[*] 

 8.0 INDEMNITY AND LIMITATION OF
LIABILITY: 
 8.1 The Licensee hereby indemnifies, holds harmless and defends the University, its Board of Governors, officers,
employees, faculty, students, invitees, and agents against any and all claims (including all legal fees and disbursements incurred in association therewith) arising out of the exercise of any rights under this Agreement including, without limiting
the generality of the foregoing, against any damages or losses, consequential or otherwise, arising from or out of the use of the Technology or Products licensed under this Agreement by the Licensee or its sublicensees, or their customers or
end-users howsoever the same may arise. 
 8.2 Subject to Article 8.3, the University’s total liability, /whether under the express or
implied terms of this Agreement, in tort (including negligence), or at common law, for any loss or damage suffered by the Licensee, whether direct, indirect, special, or any other similar or like damage that may arise or does arise from any breaches
of this Agreement by the University, its Board of Governors, officers, employees, faculty, students, or agents shall be limited to the sum of [*]. 
 8.3 In no event shall the University be liable for consequential or incidental damages arising from any breach or breaches of this Agreement. 
 9.0 PUBLICATION AND CONFIDENTIALITY: 
 9.1 The Discloser’s Confidential
Information shall be developed, received, and used by the Recipient solely in furtherance of the purposes set forth in this Agreement subject to the terms and conditions set forth in this Article 9. 

9.2 The Recipient shall keep and use all of the Discloser’s Confidential Information in confidence and will not, without the Discloser’s prior
written consent, disclose any of the Discloser’s Confidential Information to any person or entity, except those of the Recipient’s officers, employees, faculty, students, consultants and professional advisors who require said Confidential
Information in performing their obligations under this Agreement. The Recipient covenants and agrees that it will initiate and maintain an appropriate internal program limiting the internal distribution of the Discloser’s Confidential
Information. 
 9.3 The Recipient shall not use, either directly or indirectly, any of the Discloser’s Confidential Information for any
purpose other than as contemplated herein without the Discloser’s prior written consent. 
  
 *Confidential Treatment Requested. 

  -
 14
 - 
  

 9.4 If the Recipient is required by judicial or administrative process to disclose any or all of the
Discloser’s Confidential Information, the Recipient shall promptly notify the Discloser and, when available allow the Discloser reasonable time to oppose such process before disclosing any Confidential Information. 

9.5 Notwithstanding any termination or expiration of this Agreement, the obligations created in this Article 9 shall survive and be binding upon the
Recipient, its successors and assigns. 
 9.6 The Licensee acknowledges that the policies of the University require that the results of the
University’s research be publishable, subject to this Article 9.0. The parties therefore agree that the inventors of the Technology shall not be restricted from presenting at symposia, national, or regional professional meetings, or from
publishing in abstracts, journals, theses, or dissertations, or otherwise, whether in printed or in electronic media, methods and results of the inventors’ research, provided however that: 

 

	 	(a)	the University provides the Licensee with copies of any proposed publication or presentation at least [*] days in advance of the submission of such proposed publication
or presentation to a journal, editor, or other third party; and 

  

	 	(b)	the Licensee has not, within [*] days after receipt of said copies, objected in writing to such proposed presentation or proposed publication in accordance with Article
9.7 of this Agreement. 

 9.7 The Licensee may object to a proposed presentation or proposed publication on the grounds that it
contains Confidential Information that was disclosed to the University by the Licensee or on the grounds that it discloses patentable subject matter which needs protection. In the event that the Licensee makes such objection on the former ground,
the Licensee shall specify the portions of the presentation or publication considered objectionable (the “Objectionable Material”). Upon receipt of notification from the Licensee that any proposed publication or disclosure
contains Objectionable Material, the University and the Licensee shall work together to revise the proposed publication or presentation to remove or alter the Objectionable Material in a manner acceptable to the Licensee, in which case the Licensee
shall withdraw its objection. The University shall co-operate in all reasonable respects in making revisions to any proposed disclosures if considered by the Licensee to contain Objectionable Material. The University shall not be restricted from
publishing or presenting the proposed disclosure as long as the Objectionable Material has been removed. In respect of any disclosures made pursuant to this Article 9.7, at the Licensee’s request, the Licensee’s Confidential Information
shall be deleted therefrom prior to such disclosure. In the event that the Licensee makes such an objection on the latter ground, thereafter the Licensee may file a patent application and the University shall ensure that its researchers refrain from
making such publication or presentation until the Licensee has filed one or more patent applications with one or more patent offices directed to such patentable subject matter, or until 3 months have elapsed from date of receipt of such written
objection from the Licensee by the University, whichever is sooner, after which the University and its researchers may proceed with said presentation or publication. For greater certainty, a provisional patent application shall be considered to be a
patent application in the United States of America for the purposes of this Agreement. 
 9.8 The Licensee requires of the University, and the
University agrees insofar as it may be permitted to do so at law, that this Agreement, and each part of it, is confidential and shall not be disclosed to third parties, as the Licensee claims that such disclosure would or

  

*Confidential Treatment Requested. 

  -
 15
 - 
  

 
could reveal commercial, scientific or technical information and would significantly harm the Licensee’s competitive position and/or interfere with the Licensee’s negotiations with
prospective sublicensees. Notwithstanding anything contained in this Article, the parties hereto acknowledge and agree that the University may identify the title of this Agreement, the parties to this Agreement, the inventors of the Technology, the
term of this Agreement, and the consideration actually paid to the University pursuant to this Agreement. 
 9.9 The University shall use its
reasonable efforts to maintain as confidential any business plans, business documents or other reports prepared by the Licensee and delivered to the University pursuant to the terms of this license agreement and which are identified in writing by
the Licensee as confidential. 
 9.10 Notwithstanding the provisions of Article 9.2, the Licensee may disclose the University’s
Confidential Information to third parties in the exercise of the Licensee’s rights under the license grant in Article 3, provided that such third parties shall have first signed a confidentiality and non-disclosure agreement protecting the
University’s Confidential Information. 
 10.0 PRODUCTION AND MARKETING: 

10.1 The Licensee shall not use any of the UBC Trade-marks or make reference to the University or its name in any advertising or publicity whatsoever,
without the prior written consent of the University, except as required by law. Without limiting the generality of the foregoing, neither party shall issue a press release with respect to this Agreement or any activity contemplated herein without
the prior review and approval of same by the other party, except as required by law. If either party is required by law to act in contravention of this Article, such party shall provide the other party with sufficient advance notice in writing to
permit the other party to bring an application or other proceeding to contest the requirement. 
 10.2 The Licensee shall use its reasonable
commercial efforts to promote, market and sell the Products and utilize the Technology and to meet or cause to be met the market demand for the Products and the utilization of the Technology. 
 10.3 If the University is of the view that the Licensee is in breach of Article 10.2, the University shall notify the Licensee and the parties hereto shall appoint a mutually acceptable person as an
independent evaluator (the “Evaluator”) to conduct the evaluation set forth in Article 10.4 . If the parties cannot agree on such an evaluator, the appointing authority shall be the British Columbia International Commercial
Arbitration Centre. 
 10.4 Unless the Parties mutually agree otherwise, the following rules and procedures shall govern the conduct of the
parties and the Evaluator before and during the investigation by the Evaluator: 
  

	 	(a)	within [*] days of the appointment of the Evaluator each party shall provide to the Evaluator and the other party copies of all documents, statements and records on
which the party intends to rely in presenting its position to the Evaluator; 

  

	 	(b)	within [*] days of the appointment of the Evaluator the Licensee shall provide to the Evaluator and the University a written summary of its position. On receipt of the
Licensee’s summary the University shall have [*] days to prepare and submit to the Licensee and the Evaluator its own summary in reply to the summary submitted by the Licensee; 

 
 *Confidential Treatment Requested. 

  -
 16
 - 
  

	 	(c)	on receipt of the documents, statements, records and summaries submitted by the parties the Evaluator shall have [*] days within which to conduct such further inquiries
as he or she may deem necessary for the purpose of reviewing the efforts made by the Licensee with respect to the promotion, marketing and sale of the Products and the Technology in compliance with the requirements of Article 10.2. For the purpose
of conducting such an inquiry, the Evaluator shall have the right to: 

  

	 	(i)	require either party to disclose any further documents or records which the Evaluator considers to be relevant; 

 

	 	(ii)	interview or question either orally (or by way of written questions) one or more representatives of either party on issues deemed to be relevant by the Evaluator;

  

	 	(iii)	make an “on site” inspection of the Licensee’s facilities; 

 

	 	(iv)	obtain if necessary, the assistance of an independent expert to provide technical information with respect to any area in which the Evaluator does not have a specific
expertise; 

 10.5 The Evaluator shall within [*] days of starting the inquiry, prepare a report setting their findings and
conclusions as to whether or not the Licensee has used reasonable efforts as specified in Article 10.2. If the Evaluator determines that the Licensee has failed to use reasonable efforts as specified in Article 10.2, then the Evaluator shall specify
in their report their conclusions as to what would constitute such reasonable efforts, and the Licensee shall thereafter make the efforts so specified. If the Licensee fails to make such efforts, after notice of termination for breach provided in
accordance with the terms of Article 17.3, then the University’s sole remedy for failure to make the efforts specified in Article 10.2 and 10.5 shall be that this Agreement may be terminated in accordance with Article 17.3. 

10.6 The report and conclusions of the Evaluator shall be delivered to the Licensee and the University, and shall be accepted by both parties as final
and binding. 
 10.7 The University may not call for more than [*] evaluation pursuant to Article 10.3 in any [*] calendar year period. The cost
of an evaluation hereunder shall be borne [*] by the Licensee and [*] by the University. At the request of the Licensee, the University will consent to the participation in any evaluation made pursuant hereto of the Licensee’s sublicensee(s).

 10.8 The Licensee agrees that it shall deliver to the University an annual report, due on December 31 of each year during the term of
this Agreement, which summarizes the major activities the Licensee has undertaken in the course of the preceding 12 months to develop and commercialize and/or market the Technology. The report will include an outline of the status of any Products in
clinical trials and the existence of any sublicenses of the Technology. 
 11.0 ACCOUNTING RECORDS: 

11.1 The Licensee shall maintain at its principal place of business, or such other place as may be most convenient, separate accounts and records of
business done pursuant to this Agreement, such accounts and records to be in sufficient detail to enable proper returns to be made under this Agreement, and the Licensee shall cause its sublicensees to keep similar accounts and records. 

 
 *Confidential Treatment Requested. 

  -
 17
 - 
  

 11.2 The Licensee shall deliver to the University on the date [*] days after each and every Royalty Due
Date, together with the Royalty payable thereunder, the Accounting (and a report identifying each sublicensee and the principal location of the business of each sublicensee). 
 11.3 The calculation of Royalties shall be carried out in accordance with generally accepted Canadian accounting principles or the standards and principles adopted by the U.S. Financial Accounting
Standards Board, applied on a consistent basis. 
 11.4 The Licensee shall retain the accounts and records referred to in Article 11.1 above for
at least [*] years after the date upon which they were made and shall permit any duly authorized representative of the University, on reasonable notice no more than [*], to inspect such accounts and records during normal business hours of the
Licensee at the University’s expense. The Licensee shall furnish such reasonable evidence as such representative will deem necessary to verify the Accounting and will permit such representative to make copies of or extracts from such accounts,
records and agreements at the University’s expense. 
 11.5 During the term of this Agreement and thereafter, the University shall use
reasonable efforts to ensure that all information provided to the University or its representatives pursuant to this Article remains confidential and is treated as such by the University. 
 12.0 INSURANCE: 
 12.1 Unless satisfactory arrangements are made between the Licensee
and the University with respect to a self-insurance program or the requirement for insurance hereunder is waived by the University [*] days prior to the start of any human clinical trials or other Product testing involving human subjects by the
Licensee or any sublicensee (“Human Clinical Trials”), then the Licensee shall procure and maintain, during the term of this Agreement, the insurance outlined in Articles 12.2 and 12.3 and otherwise comply with the insurance
provisions contained in Articles 12.2 and 12.3. 
 12.2 The Licensee shall give written notice to the University [*] days prior to the earlier
of either: 
  

	 	(a)	the start of any Human Clinical Trials; or 

  

	 	(b)	the first sale of any Product by the Licensee or any Affiliate or sublicensee; 

 of the terms and amount of the appropriate public liability, product liability and errors and omissions insurance which it has placed. Such insurance shall in no case be less than the insurance which a
reasonable and prudent businessperson carrying on a similar line of business would acquire. This insurance shall be placed with a reputable and financially secure insurance carrier, shall include the University, its Board of Governors, faculty,
officers, employees, students, and agents as additional insureds, and shall provide primary coverage with respect to the activities contemplated by this Agreement. Such policy shall not be cancelled or materially altered except upon at least [*]
days’ written notice to the University. Failing the parties agreeing on the appropriate terms or the amount of coverage, then the matter shall be determined by arbitration as provided for herein. The Licensee shall provide the University with
certificates of insurance evidencing such coverage [*] days before commencement of Human Clinical Trials and [*] days prior to the sales of any Product and the Licensee covenants not to start Human Clinical Trials, or sell any Product before such
certificate is provided and approved by the University, or to start any Human Clinical Trials or sell any Product at any time unless the insurance outlined in this Article 12.2 is in effect. 
  
 *Confidential Treatment Requested. 

  -
 18
 - 
  

 12.3 The Licensee shall require that each sublicensee under this Agreement shall either: 

 

	 	(a)	demonstrate to the Licensee’s reasonable satisfaction that such sublicensee has a program of self insurance no less adequate than that which a reasonable and
prudent businessperson carrying on a similar line of business would require; or 

  

	 	(b)	[*] days prior to the earlier of the start of Human Clinical Trials or the first sale of any Product by such sublicensee, procure and maintain public liability, product
liability and errors and omissions insurance in reasonable amounts, with a reputable and financially secure insurance carrier. The Licensee shall use reasonable efforts to ensure that any and all such policies of insurance required pursuant to this
Article 12.3(b) shall contain a waiver of subrogation against the University, its Board of Governors, faculty, officers, employees, students, and agents. 

 13.0 ASSIGNMENT: 
 13.1 Except as expressly permitted hereby, the Licensee will not
assign, transfer, mortgage, charge or otherwise dispose of any or all of the rights, duties or obligations granted to it under this Agreement without the prior written consent of the University, which consent will not be unreasonably withheld.
Notwithstanding the foregoing, the Licensee shall have the right to assign to an Affiliated Company or an entity that acquires all, or substantially all, of the assets related to the Technology and the Products. 

13.2 The University shall have the right to assign its rights, duties and obligations under this Agreement to a company or society of which it is the
sole shareholder in the case of a company or of which it controls the membership, in the case of a society. 
 14.0 GOVERNING LAW AND
ARBITRATION: 
 14.1 This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia
and the laws of Canada in force therein without regard to its conflict of law rules. All parties agree that by executing this Agreement they have attorned to the jurisdiction of the Supreme Court of British Columbia. Subject to Articles 14.2 and
14.3, the courts of British Columbia shall have exclusive jurisdiction over this Agreement. 
 14.2 In the event of any dispute arising between
the parties concerning this Agreement, its enforceability or the interpretation thereof, the same shall be settled by a single arbitrator appointed pursuant to the provisions of the Commercial Arbitration Act of British Columbia, or any successor
legislation then in force. The place of arbitration shall be Vancouver, British Columbia. The language to be used in the arbitration proceedings shall be English. 
 14.3 Article 14.2 shall not prevent a party hereto from applying to a court of competent jurisdiction for interim protection such as, by way of example, an interim injunction. 

14.4 Notwithstanding the rest of this Article 14, if a ruling by a court or arbitral authority on any dispute between the Licensee and a sublicensee,
regarding the interpretation 
  
 *Confidential
Treatment Requested. 

  -
 19
 - 
  

 
of the sublicensee’s sublicense agreement, could reasonably affect the interpretation of this Agreement, then on receipt of notice of such a dispute from the Licensee, the University may
elect to apply to join in such proceeding. 
  

	 	(a)	If the University is permitted to join in such proceeding it shall be bound by the decision of such court or arbitral authority, in so far as the interpretation of such
decision could reasonably affect the interpretation of this Agreement. 

  

	 	(b)	If the University elects not to join in such proceeding (for reasons other than not being permitted to join) then the University hereby agrees to be bound by the
decision of such court or arbitral authority, in so far as the interpretation of such decision could reasonably affect the interpretation of this Agreement. 

 

	 	(c)	If the University is not permitted to join in such proceeding, then the University shall not be bound by the decision of such court or arbitral authority.

 [*] 
 15.0
NOTICES: 
 15.1 All payments, reports and notices or other documents that any of the parties hereto are required or may desire to
deliver to any other party hereto may be delivered only by personal delivery or by registered or certified mail, or fax, all postage and other charges prepaid, at the address for such party set forth below or at such other address as any party may
hereinafter designate in writing to the others. Any notice personally delivered or sent by fax shall be deemed to have been given or received at the time of delivery, or transmission of the fax. Any notice mailed as aforesaid shall be deemed to have
been received on the expiration of [*] after it is posted, provided that if there shall be at the time of mailing or between the time of mailing and the actual receipt of the notice a mail strike, slow down or labour dispute which might affect the
delivery of the notice by the mail, then the notice shall only be effected if actually received. 
  

			
	 If to the University:
	  	 [*]
 [*]

[*]
 [*]

[*]
 [*]

[*]
 [*]

 
 *Confidential Treatment Requested. 

  -
 20
 - 
  

																																							
	 If to the Licensee:
	  	 [*]

[*]
 [*]

[*]
 [*]

[*]
 [*]

16.0 TERM: 
 16.1 This Agreement
and the license granted hereunder shall terminate on the expiration of a term of [*] years from the Date of Commencement or the expiration of the last patent obtained pursuant to Article 6 herein, whichever event shall last occur unless earlier
terminated pursuant to Article 17 herein. Upon expiry of the term of this Agreement (but not on termination in accordance with Article 17) the Licensee shall thereafter have, in perpetuity, a fully paid-up world wide license to use and sublicense
the Technology and to manufacture, have made, distribute, import, use and sell Products, without further payment of Royalties to the University. 
 17.0 TERMINATION: 
 17.1 This Agreement shall automatically and immediately terminate
without notice to the Licensee if any proceeding under any applicable bankruptcy or insolvency laws, or any other legislation of similar purport, is commenced by or against the Licensee, provided that in the case of any involuntary bankruptcy or
insolvency proceedings being commenced against the Licensee, the Licensee shall have a [*] day period following the commencement of any such proceedings, and, if such proceedings are discharged within such period, the termination shall be of no
effect. 
 17.2 The University may, at its option, terminate this Agreement immediately on the happening of any one or more of the following
events by delivering notice in writing to that effect to the Licensee: 
  

	 	(a)	if any execution, sequestration, or any other process of any court becomes enforceable against the Licensee or if any such process is levied on the rights under this
Agreement or upon any of the monies due to the University and is not released or satisfied by the Licensee within [*] days thereafter; 

  

	 	(b)	if any resolution is passed by the Licensee or voluntary order made or other steps taken by the Licensee for the winding up, liquidation or other termination of the
existence of the Licensee; 

  

	 	(c)	if the Licensee ceases to carry on its business, other than as a result of a disposition of substantially all of the Licensee’s business to a third party;

  

	 	(d)	if the Licensee commits any breach of Article 4.1 or any material breach of Article 12; 

 

	 	(e)	the Licensee notifies the University in writing that it intends to discontinue pursuing all Patent protection for the Technology as set out in Article 6.6(a) hereof;

  
 *Confidential Treatment Requested.

  -
 21
 - 
  

	 	(f)	if any sublicensee of the Licensee is in material breach of its sublicense agreement with the Licensee which breach would be a breach of this Agreement if committed by
the Licensee and the Licensee fails to use reasonable efforts to cause such sublicensee to cure such breach within [*] days of receipt of written notice from the University requiring that the Licensee cause such sublicensee to cure such breach; or

  

	 	(g)	if the Licensee is in breach of the Collaborative Research Agreement between the Licensee and the University, which breach has not been cured within the time provided
for the curing of such breach under the terms of the Collaborative Research Agreement, provided that the University’s notice of breach of such agreement states its intention to terminate this Agreement. 

17.3 Other than as set out in Articles 17.1 and 17.2, if either party shall be in default under or shall fail to comply with the terms of this Agreement
then the non-defaulting party shall have the right to terminate this Agreement by written notice, (such written notice expressly stating the grounds for the default), to that effect if: 

 

	 	(a)	such default is reasonably curable within [*] days after receipt of notice of such default and such default or failure to comply is not cured within [*] days after
receipt of written notice thereof, or 

  

	 	(b)	such default is not reasonably curable within [*] days after receipt of written notice thereof, and such default or failure to comply is not cured within such further
reasonable period of time as may be necessary for the curing of such default or failure to comply. 

 17.4 If this Agreement is
terminated pursuant to Articles 17.1, 17.2, or 17.3, the Licensee shall make Royalty payments to the University in the manner specified in Article 5, and the University may proceed to enforce payment of all outstanding Royalties or other monies owed
to the University and to exercise any or all of the rights and remedies contained herein or otherwise available to the University by law or in equity, successively or concurrently at the option of the University. 

17.5 Upon any such termination of this Agreement, the Licensee shall: 
  

	 	(a)	except as required by law or expressly permitted by Article 17.7, deliver up to the University within a reasonable time, not to exceed [*] months from the Effective
Date of Termination, all Technology in its possession or control and shall have no further right of any nature whatsoever in the Technology. On failure by the Licensee to so deliver up the Technology, the University may take action against the
Licensee to enforce such delivery and the Licensee will pay all charges or expenses incurred by the University in the enforcement of such rights or remedies against the Licensee including, without limitation, the University’s legal fees and
disbursements on an indemnity basis, and 

  

	 	(b)	 deliver to the University within [*] days of the Effective Date of Termination a written accounting and plan specifying, in such terms as the
University may in its reasonable discretion require, the inventory of Products remaining unsold on the Effective Date of Termination, and the Licensee’s plan for the disposition of same. Following the delivery of such accounting and plan, the
Licensee shall then have a reasonable time to liquidate such inventory of Products, provided 

  

*Confidential Treatment Requested. 

  -
 22
 - 
  

	 	 
that such period shall not exceed [*] months from the Effective Date of Termination. The Licensee shall continue to make all Royalty payments to the University on all such Products sold in the
same manner as specified in this Agreement, notwithstanding anything contained in, or any exercise of rights by the University under this Article 17. 

 17.6 Notwithstanding the termination of this Agreement, Article 11 shall remain in full force and effect until [*] years after: 

 

	 	(a)	all payments of Royalty required to be made by the Licensee to the University under this Agreement have been made by the Licensee to the University, and

  

	 	(b)	any other claim or claims of any nature or kind whatsoever of the University against the Licensee has been settled. 

17.7 Except as required by law, upon any termination of this Agreement, each party shall cease to use the Confidential Information of the other party,
and upon written request and at the option of the other party, shall deliver or destroy and certify the destruction of all copies of same, except for a single copy to be retained solely for the purpose of compliance with the terms of this Agreement.

 18.0 MISCELLANEOUS COVENANTS OF LICENSEE: 
 18.1 The Licensee hereby represents and warrants to the University that the Licensee is a corporation duly organized, existing, and in good standing under the laws of the Province of British Columbia and
has the power, authority, and capacity to enter into this Agreement and to carry out the transactions contemplated by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings. 

18.2 The Licensee represents and warrants that it has the expertise necessary to handle the Technology with care and without danger to the Licensee, its
employees, agents, or the public. The Licensee shall not accept delivery of the Technology until it has requested and received from the University all necessary information and advice to ensure that it is capable of handling the Technology in a safe
and prudent manner. 
 18.3 The Licensee shall comply with all laws, regulations and ordinances, whether Federal, Provincial, Municipal or
otherwise with respect to the Technology and/or this Agreement. 
 18.4 Upon the presentation of itemized bills to the Licensee by the
University, the Licensee shall pay: 
  

	 	(a)	all reasonable legal expenses and costs incurred by the University in respect of the negotiation and preparation of this Agreement, and of any amendments of this
Agreement; and 

  

	 	(b)	all reasonable legal expenses and costs in excess of [*], incurred by the University in respect of any consents or approvals required from the University, including but
not limited to expenses and costs in respect of the University’s review of each sublicense to be granted by the Licensee, but not including litigation expenses incurred by the University as set out in Article 7.5. 

 
 *Confidential Treatment Requested. 

  -
 23
 - 
  

 18.5 The Licensee shall pay all taxes and any related interest or penalty howsoever designated and
imposed as a result of the existence or operation of this Agreement, including, but not limited to, tax which the Licensee is required to withhold or deduct from payments to the University. The Licensee will furnish to the University such evidence
as may be required by Canadian authorities to establish that any such tax has been paid. The Royalties specified in this Agreement are exclusive of taxes. If the University is required to collect a tax to be paid by the Licensee (or any of its
sublicensees), the Licensee shall pay such tax to the University on demand. 
 19.0 RESEARCH AGREEMENT: 

19.1 The Licensee and the University hereby confirm the provisions of the Collaborative Research Agreement. 

19.2 If there is a conflict of the provisions of this Agreement and the provisions of the Collaborative Research Agreement, the provisions of this
Agreement shall govern. 
 20.0 GENERAL: 
 20.1 On reasonable notice, the Licensee shall permit any duly authorized representative of the University during normal business hours and at the University’s sole risk and expense to enter upon and
into any premises of the Licensee for the purpose of inspecting the Products and the manner of their manufacture and generally of ascertaining whether or not the provisions of this Agreement have been, are being, or will be complied with by the
Licensee. 
 20.2 Nothing contained herein shall be deemed or construed to create between the parties hereto a partnership or joint venture. No
party shall have the authority to act on behalf of any other party, or to commit any other party in any manner or cause whatsoever or to use any other party’s name in any way not specifically authorized by this Agreement. No party shall be
liable for any act, omission, representation, obligation or debt of any other party, even if informed of such act, omission, representation, obligation or debt. 
 20.3 Subject to the limitations hereinbefore expressed, this Agreement shall enure to the benefit of and be binding upon the parties, and their respective successors and permitted assigns. 

20.4 No condoning, excusing or overlooking by any party of any default, breach or non-observance by any other party at any time or times in respect of
any covenants, provisos, or conditions of this Agreement shall operate as a waiver of such party’s rights under this Agreement in respect of any continuing or subsequent default, breach or non-observance, so as to defeat in any way the rights
of such party in respect of any such continuing or subsequent default or breach and no waiver shall be inferred from or implied by anything done or omitted by such party, save only an express waiver in writing. 

20.5 No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing another remedy or
maintaining an action to which it may otherwise be entitled either at law or in equity. 
 20.6 Marginal headings as used in this Agreement are
for the convenience of reference only and do not form a part of this Agreement and are not be used in the interpretation hereof. 

  -
 24
 - 
  

 20.7 The terms and provisions, covenants and conditions contained in this Agreement which by the terms
hereof require their performance by the parties hereto after the expiration or termination of this Agreement shall be and remain in force notwithstanding such expiration or other termination of this Agreement for any reason whatsoever. 

20.8 If any Article, part, section, clause, paragraph or subparagraph of this Agreement shall be held to be indefinite, invalid, illegal or otherwise
voidable or unenforceable, the entire agreement shall not fail on account thereof, and the balance of the Agreement shall continue in full force and effect. 
 20.9 The parties hereto acknowledge that the law firm of Richards Buell Sutton has acted solely for the University in connection with this Agreement and that all other parties hereto have been advised to
seek independent legal advice. 
 20.10 All amounts due and owing to the University hereunder but not paid by the Licensee on the due date
thereof shall bear interest in Canadian dollars at the rate of [*]. Such interest shall accrue on the balance of unpaid amounts from time to time outstanding from the date on which portions of such amounts become due and owing until payment thereof
in full. 
 20.11 This Agreement sets forth the entire understanding between the parties and no modifications hereof shall be binding unless
executed in writing by the parties hereto. 
 20.12 Whenever the singular or masculine or neuter is used throughout this Agreement the same
shall be construed as meaning the plural or feminine or body corporate when the context or the parties hereto may require. 
 IN
WITNESS WHEREOF the parties hereto have hereunto executed this Agreement on the 30 day of June    , 2001 but effective as of the Date of Commencement. 
 Signed for and on behalf of 
 THE UNIVERSITY OF BRITISH COLUMBIA 

by its duly authorized officer: 
  

			
	/s/ ANGUS LIVINGSTONE
		
	Name:	 	Angus Livingstone
	Title:	 	Managing Director
		 	University – Industry Liaison Office
	Date:	 	June 30, 2001

  

*Confidential Treatment Requested. 

  -
 25
 - 
  

 Signed for and on behalf of 
 INEX PHARMACEUTICALS CORPORATION 
 by its duly authorized officer: 

 

			
	/s/ DAVID J. MAIN
		
	Name:	 	David J. Main
	Title:	 	President and CEO
	Date:	 	July 26, 2001

 SCHEDULE “A” 

DESCRIPTION OF “TECHNOLOGY” 
 PART I: 
 The Technology and Patents which are subject to the Collaborative Research
Agreement or as otherwise agreed by the parties, and set out more specifically as follows: 

 - A2 - 

 

															
	 UBC File #
	  	Inex File #	 	 Description
	  	 Patent #’s
	  	Inventors	 	Party
Credited	 	UBC
Royalty	 	UBC
Sublicense
Royalty
	 [*]
	  	[*]	 	[*]	  	[*]	  	[*]	 	[*]	 	[*]	 	[*]

  
 *Confidential Treatment Requested. 

 - A3 - 

 

 PART II 
 The Technology and Patents which were originally licensed to the Licensee pursuant to the terms of the 1998 License and set out more specifically as follows: 

 - A4 - 

 

															
	 UBC File #
	  	Inex File #	 	 Description
	  	 Patent #’s
	  	Inventors	 	Party
Credited	 	UBC
Royalty	 	UBC
Sublicense
Royalty
	 [*]
	  	[*]	 	[*]	  	[*]	  	[*]	 	[*]	 	[*]	 	[*]

 [*] 

[*] 
  
 *Confidential Treatment Requested. 

 SCHEDULE “B” 

ROYALTIES 
 [*]

  
 *Confidential Treatment Requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]